Publications and communications of Edouard Louis

Guiot, J., André, B., Potjewijd, J., JACQUERIE, P., Cremers, S., Henket, M., Idoufkir, L., Remacle, C., Tobal, R., GILTAY, L., Moermans, C., GESTER, F., Polese, B., Hamaïdia, M., Struman, I., Louis, E., Malaise, M., de Seny, D., van Paassen, P., ... Njock, M.-S. (2025). Association of fibrotic-related extracellular vesicle microRNAs with lung involvement in systemic sclerosis. European Respiratory Journal, 2400276. doi:10.1183/13993003.00276-2024

TRIEU, T.-H., Vieujean, S., DELHOUGNE, N., Seidel, L., Louis, E., & Loly, J.-P. (2025). Confocal Endomicroscopy Intestinal Epithelial Barrier Abnormalities in Individuals Without Documented Gastro-Intestinal Disease. United European Gastroenterology Journal. doi:10.1002/ueg2.12756

Panés, J., Louis, E., Bossuyt, P., Joshi, N., Lee, W.-J., Lacerda, A. P., Kligys, K., Xuan, S., Shukla, N., & Loftus, E. V. J. (2025). Induction of Endoscopic Response, Remission, and Ulcer-Free Endoscopy With Upadacitinib Is Associated With Improved Clinical Outcomes and Quality of Life in Patients With Crohn's Disease. Inflammatory Bowel Diseases. doi:10.1093/ibd/izae200

Pierre, N., Jacobs, N., Fernández-Verdejo, R., Louis, E., & Vieujean, S. (January 2025). P0129 Distinct involvement of plasma cells and monocytes/macrophages in ileal and colonic ulcer formation in patients with Crohn's disease. Journal of Crohn's and Colitis, 19 (Supplement_1), 513-i514. doi:10.1093/ecco-jcc/jjae190.0303

Ghosh, S., Feagan, B. G., Parra, R. S., Lopes, S., Steinlauf, A., Kakuta, Y., Joshi, N., Lee, W.-J., Lacerda, A. P., Zhou, Q., Xuan, S., Kligys, K., Shukla, N., & Louis, E. (04 November 2024). Impact of Upadacitinib Induction and Maintenance Therapy on Health-related Quality of Life, Fatigue, and Work Productivity in Patients with Moderately-to-severely Active Crohn's Disease. Journal of Crohn's and Colitis, 18 (11), 1804-1818. doi:10.1093/ecco-jcc/jjae083

Parigi, T. L., Solitano, V., Armuzzi, A., Barreiro de Acosta, M., Begun, J., Ben-Horin, S., Biedermann, L., Colombel, J.-F., Dignass, A., Fumery, M., Ghosh, S., Kobayashi, T., Louis, E., Magro, F., Panaccione, R., Rausch, A., Reinisch, W., Selinger, C., Jairath, V., ... Peyrin-Biroulet, L. (November 2024). Defining mucosal healing in randomized controlled trials of inflammatory bowel disease: A systematic review and future perspective. United European Gastroenterology Journal, 12 (9), 1266-1279. doi:10.1002/ueg2.12671

Schreiber, S., Feagan, B. G., Louis, E., Hisamatsu, T., Hibi, T., Dron, L., Jamoul, C., Patel, H., Harris, K., Taliadouros, V., Oortwijn, A., & Peyrin-Biroulet, L. (November 2024). Distinct trajectories of symptomatic response in ulcerative colitis during filgotinib therapy: A post hoc analysis from the SELECTION study. United European Gastroenterology Journal, 12 (9), 1243-1255. doi:10.1002/ueg2.12686

Capirchio, L., Rousseaux, C., Dubuquoy, C., Ouwehand, A. C., Maquet, V., Modica, S., Louis, E., Desreumaux, P., & Tack, J. (05 October 2024). A Synbiotic Combining Chitin-Glucan and Lactobacillus acidophilus NCFM Induces a Colonic Molecular Signature Soothing Intestinal Pain and Inflammation in an Animal Model of IBS. International Journal of Molecular Sciences, 25 (19). doi:10.3390/ijms251910732

Peyrin-Biroulet, L., Panaccione, R., Louis, E., Atreya, R., Rubin, D. T., Lindsay, J. O., Siffledeen, J., Lukin, D. J., Wright, J., Watanabe, K., Ford, S., Remple, V. P., Lacerda, A. P., Dubcenco, E., Garrison, A., Zhou, Q., Berg, S., Anyanwu, S. I., & Schreiber, S. (October 2024). Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn's Disease Regardless of Prior Biologic Exposure. Clinical Gastroenterology and Hepatology, 22 (10), 2096-2106. doi:10.1016/j.cgh.2024.02.026

Schreiber, S., Cross, R. K., Panaccione, R., D'Haens, G., Bossuyt, P., Dotan, I., Colombel, J.-F., Louis, E., Dubinsky, M. C., Kligys, K., Neimark, E., Song, A., Zambrano, J., Kalabic, J., Cheng, E., Zhang, Y., & Ferrante, M. (October 2024). Efficacy and safety of risankizumab by baseline corticosteroid use and achievement of corticosteroid-free clinical and endoscopic outcomes in patients with moderately to severely active Crohn's disease. Alimentary Pharmacology and Therapeutics, 60 (7), 897-906. doi:10.1111/apt.18184

Louis, E., Schreiber, S., Panaccione, R., Bossuyt, P., Biedermann, L., Colombel, J.-F., Parkes, G., Peyrin-Biroulet, L., D'Haens, G., Hisamatsu, T., Siegmund, B., Wu, K., Boland, B. S., Melmed, G. Y., Armuzzi, A., Levine, P., Kalabic, J., Chen, S., Cheng, L., ... Zisman, T. (Other coll.). (17 September 2024). Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials. JAMA: Journal of the American Medical Association, 332 (11), 881-897. doi:10.1001/jama.2024.12414

Pierre, N., Huynh-Thu, V. A., Baiwir, D., Mazzucchelli, G., Fleron, M., Trzpiot, L., Eppe, G., De Pauw, E., Laharie, D., Satsangi, J., Bossuyt, P., Vuitton, L., Vieujean, S., Colombel, J.-F., Meuwis, M.-A., Louis, E., & GETAID and the SPARE-Biocycle research group. (2024). External validation of serum biomarkers predicting short-term and mid/long-term relapse in patients with Crohn's disease stopping infliximab. Gut, 2024-332648. doi:10.1136/gutjnl-2024-332648

Ernst, M., Maes, N., Louis, E., Anhorn, P., & Wieser, P. (Eds.). (2024). Actes du congrès Alass-Giseh 2024 Ensemble ! Les Enjeux du travail en réseau dans le domaine de la santé. Liège, Belgium: Alass-Giseh 2024.

Preda, C. M., Istratescu, D., Nitescu, M., Manuc, T., Manuc, M., Stroie, T., Tieranu, C., Meianu, C. G., Andrei, A., Ciora, C. A., Louis, E., & Diculescu, M. (29 June 2024). Diet Optimization in Inflammatory Bowel Disease: Impact on Disease Relapse and Inflammatory Markers. A 1-year Prospective Trial. Journal of Gastrointestinal and Liver Diseases, 33 (2), 184-193. doi:10.15403/jgld-5482

Louis, E., Litkiewicz, M., Agboton, C., & Armuzzi, A. (June 2024). Therapeutic sequencing in inflammatory bowel disease: Determining the optimal position of vedolizumab for long-term Crohn's disease control using real-world evidence. United European Gastroenterology Journal, 12 (5), 574-584. doi:10.1002/ueg2.12563

Caenepeel, C., Deleu, S., Vazquez Castellanos, J. F., Arnauts, K., Braekeleire, S., Machiels, K., Baert, F., Mana, F., Pouillon, L., Hindryckx, P., Lobaton, T., Louis, E., Franchimont, D., Verstockt, B., Ferrante, M., Sabino, J., Vieira-Silva, S., Falony, G., Raes, J., & Vermeire, S. (2024). Rigorous Donor Selection for Fecal Microbiota Transplantation in Active Ulcerative Colitis: Key Lessons From a Randomized Controlled Trial Halted for Futility. Clinical Gastroenterology and Hepatology. doi:10.1016/j.cgh.2024.05.017

Pierre, N., Huynh-Thu, V. A., Baiwir, D., VIEUJEAN, S., Bequet, E., Reenaers, C., Van Kemseke, C., Salée, C., Massot, C., Fleron, M., Mazzucchelli, G., Trzpiot, L., Eppe, G., De Pauw, E., Louis, E., & Meuwis, M.-A. (2024). Serum proteome signatures associated with ileal and colonic ulcers in Crohn's disease. Journal of Proteomics, 105199. doi:10.1016/j.jprot.2024.105199

Peyrin-Biroulet, L., Arkkila, P., Armuzzi, A., Danese, S., Ferrante, M., Jordi, G., Jahnsen, J., Louis, E., Lukáš, M., Reinisch, W., Roblin, X., Smith, P. J., Kwon, T., Kim, J., Yoon, S., Kim, D.-H., & Atreya, R. (27 March 2024). Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trials. BMC Gastroenterology, 24 (1), 121. doi:10.1186/s12876-024-03163-5

Xiong, W., Anthony, D. C., Anthony, S., Ho, T. B. T., Louis, E., Satsangi, J., & Radford-Smith, D. E. (12 February 2024). Sodium fluoride preserves blood metabolite integrity for biomarker discovery in large-scale, multi-site metabolomics investigations. Analyst, 149 (4), 1238-1249. doi:10.1039/d3an01359f

Focant, J.-F., Bhatt, K., Orlando, T., Meuwis, M.-A., Louis, E., & Stefanuto, P.-H. (2024). Targeted Blood Lipidomics of Colorectal Cancer [Paper presentation]. HTC18.

Peyrin-Biroulet, L., Colombel, J.-F., Louis, E., Ferrante, M., Motoya, S., Panaccione, R., Torres, J., Ungaro, R. C., Kligys, K., Kalabic, J., Zambrano, J., Zhang, Y., & D'Haens, G. (2024). Shorter Crohn's Disease Duration Is Associated With Better Clinical and Endoscopic Outcomes With Risankizumab in Phase 3 Studies. Gastro Hep Advances, 3 (4), 539-550. doi:10.1016/j.gastha.2024.02.008

Weerts, F., Loly, C., & Louis, E. (December 2023). Colites iatrogènes sur immunothérapie : étude rétrospective au CHU de Liège. Revue Médicale de Liège, 78 (12), 703-709.

Martinez, E., Crevecoeur, S., THIRION, C., GRANDJEAN, J., Fall, P. A., Hayette, M.-P., Moutschen, M., Taminiau, B., Louis, E., & Daube, G. (10 October 2023). Gut Microbiota Associated with Clostridioides difficile Carriage in Three Clinical Groups (Inflammatory Bowel Disease, C. difficile Infection and Healthcare Workers) in Hospital Field. Microorganisms, 11 (10), 2527. doi:10.3390/microorganisms11102527

Gonza Quito, I. E., Goya-Jorge, E., Douny, C., Scippo, M.-L., Louis, E., & Delcenserie, V. (04 October 2023). Sucralose and maltodextrin affect differently the gut microbiota of healthy individuals and IBD patients [Poster presentation]. BENEFIQ 2023, Québec, Canada.

Baumdick, M. E., Niehrs, A., Degenhardt, F., Schwerk, M., Hinrichs, O., Jordan-Paiz, A., Padoan, B., Wegner, L. H. M., Schloer, S., Zecher, B. F., Malsy, J., Joshi, V. R., Illig, C., Schröder-Schwarz, J., Möller, K. J., Hamburg Intestinal Tissue Study, G., Martin, M. P., Yuki, Y., Ozawa, M., ... Zhao, Z. Z. (Other coll.). (October 2023). HLA-DP on Epithelial Cells Enables Tissue Damage by NKp44(+) Natural Killer Cells in Ulcerative Colitis. Gastroenterology, 165 (4), 946-962.e13. doi:10.1053/j.gastro.2023.06.034

Pierre, N., VIEUJEAN, S., Meuwis, M.-A., & Louis, E. (2023). Définir la rémission biologique dans la maladie de Crohn. Medi-Sphere.

Di Giovanni, N., Meuwis, M.-A., Louis, E., & Focant, J.-F. (23 September 2023). Correlations for untargeted GC × GC-HRTOF-MS metabolomics of colorectal cancer. Metabolomics, 19 (10), 85. doi:10.1007/s11306-023-02047-1

Lemmens, P., Louis, E., Van Moerkercke, W., Pouillon, L., Somers, M., Peeters, H., Vanden Branden, S., Busschaert, J., Baert, F., Cremer, A., Potvin, P., Dewit, S., Colard, A., Swinnen, J., Lambrecht, G., Claessens, C., Willandt, B., Dewint, P., Van Dyck, E., ... Ferrante, M. (2023). Outcome of Biological Therapies and Small Molecules in Ulcerative Proctitis: A Belgian Multicenter Cohort Study. Clinical Gastroenterology and Hepatology. doi:10.1016/j.cgh.2023.06.023

Bhatt, K., Orlando, T., Meuwis, M.-A., Louis, E., Stefanuto, P.-H., & Focant, J.-F. (01 June 2023). Comprehensive Insight into Colorectal Cancer Metabolites and Lipids for Human Serum: A Proof-of-Concept Study. International Journal of Molecular Sciences, 24 (11), 9614. doi:10.3390/ijms24119614

Latour, P., & Louis, E. (2023). La colopathie fonctionnelle : toujours d’actualité ? Place au syndrome de l’intestin irritable. Revue Médicale de Liège.

Preda, C. M., Istratescu, D., Nitescu, M., Manuc, T., Manuc, M., Stroie, T., Catrinoiu, M., Tieranu, C., Meianu, C. G., Tugui, L., Ciora, C. A., Louis, E., & Diculescu, M. (June 2023). Impact of Dietary Patterns in Inflammatory Bowel Disease Subtypes Versus Healthy Subjects: a Retrospective Cohort Study. Mædica, 18 (2), 174-181. doi:10.26574/maedica.2023.18.2.174

Bacha, R. A., Bouhnik, Y., Serrero, M., Filippi, J., Roblin, X., Bourrier, A., Bouguen, G., Franchimont, D., Savoye, G., Buisson, A., Louis, E., Nancey, S., Abitbol, V., Reimund, J.-M., DeWit, O., Vuitton, L., Mathieu, N., Peyrin-Biroulet, L., Gilletta, C., ... Picon, L. (Other coll.). (2023). Obesity in adult patients with inflammatory bowel disease: Clinical features and impact on disability. A cross-sectional survey from the GETAID. Digestive and Liver Disease. doi:10.1016/j.dld.2023.05.008

Loftus, E. V. J., Panés, J., Lacerda, A. P., Peyrin-Biroulet, L., D'Haens, G., Panaccione, R., Reinisch, W., Louis, E., Chen, M., Nakase, H., Begun, J., Boland, B. S., Phillips, C., Mohamed, M.-E. F., Liu, J., Geng, Z., Feng, T., Dubcenco, E., & Colombel, J.-F. (25 May 2023). Upadacitinib Induction and Maintenance Therapy for Crohn's Disease. New England Journal of Medicine, 388 (21), 1966-1980. doi:10.1056/NEJMoa2212728

Pierre, N., Vieujean, S., Peyrin-Biroulet, L., Meuwis, M.-A., & Louis, E. (2023). Defining biological remission in Crohn's disease: interest, challenges and future directions. Journal of Crohn's and Colitis. doi:10.1093/ecco-jcc/jjad086

Gonza Quito, I. E., Goya-Jorge, E., Douny, C., Scippo, M.-L., Louis, E., & Delcenserie, V. (02 May 2023). Do polysorbate 80 and sodium nitrite affect differently the gut microbiota of healthy individuals and IBD patients ? [Paper presentation]. IAFP's European symposium, Aberdeen, United Kingdom.

Liu, Z., Liu, R., Gao, H., Jung, S., Gao, X., Sun, R., Liu, X., Kim, Y., Lee, H.-S., Kawai, Y., Nagasaki, M., Umeno, J., Tokunaga, K., Kinouchi, Y., Masamune, A., Shi, W., Shen, C., Guo, Z., Yuan, K., ... Guo, Z. (Other coll.). (May 2023). Genetic architecture of the inflammatory bowel diseases across East Asian and European ancestries. Nature Genetics, 55 (5), 796-806. doi:10.1038/s41588-023-01384-0

Guiot, J., Henket, M., Remacle, C., Cambier, M., Struman, I., Winandy, M.-L., Moermans, C., Louis, E., Malaise, M., Ribbens, C., Louis, R., & Njock, M.-S. (15 April 2023). Systematic review of overlapping microRNA patterns in COVID-19 and idiopathic pulmonary fibrosis. Respiratory Research, 24 (1), 112. doi:10.1186/s12931-023-02413-6

Horrigan, J. M., Louis, E., Spinelli, A., Travis, S., Moum, B., Salwen-Deremer, J., Halfvarson, J., Panaccione, R., Dubinsky, M. C., Munkholm, P., & Siegel, C. A. (April 2023). The Real-World Global Use of Patient-Reported Outcomes for the Care of Patients With Inflammatory Bowel Disease. Crohn's & colitis 360, 5 (2), 006. doi:10.1093/crocol/otad006

Amiot, A., Chaibi, S., Bouhnik, Y., Serrero, M., Filippi, J., Roblin, X., Bourrier, A., Bouguen, G., Franchimont, D., Savoye, G., Buisson, A., Louis, E., Nancey, S., Abitbol, V., Reimund, J.-M., Dewit, O., Vuitton, L., Mathieu, N., Peyrin-Biroulet, L., ... GETAID-patient experience study, G. (2023). Prevalence and determinants of fatigue in patients with IBD: a cross-sectional survey from the GETAID. Journal of Crohn's and Colitis. doi:10.1093/ecco-jcc/jjad060

Louis, E., Resche-Rigon, M., Laharie, D., Satsangi, J., Ding, N., Siegmund, B., D'Haens, G., Picon, L., Bossuyt, P., Vuitton, L., Irving, P., Viennot, S., Lamb, C. A., Pollok, R., Baert, F., Nachury, M., Fumery, M., Gilletta, C., Almer, S., ... Roblin, X. (Other coll.). (March 2023). Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial. The Lancet Gastroenterology and Hepatology, 8 (3), 215-227. doi:10.1016/S2468-1253(22)00385-5

Nitescu, M., Istratescu, D., Preda, C. M., Manuc, T. E., Louis, E., Manuc, M., Stroie, T., Catrinoiu, M., Tieranu, C. G., Badea, L. E., Tugui, L., Andrei, A., & Diculescu, M. M. (09 February 2023). Role of an Exclusion Diet (Reduced Disaccharides, Saturated Fats, Emulsifiers, Red and Ultraprocessed Meats) in Maintaining the Remission of Chronic Inflammatory Bowel Diseases in Adults. Medicina, 59 (2). doi:10.3390/medicina59020329

Bouhnik, Y., Pineton de Chambrun, G., Lambert, J., Nachury, M., Seksik, P., Altwegg, R., Vuitton, L., Stefanescu, C., Nancey, S., Aubourg, A., Serrero, M., Filippi, J., Desseaux, K., Viennot, S., Abitbol, V., Boualit, M., Bourreille, A., Giletta, C., Buisson, A., ... Painchart, C. (Other coll.). (2023). Adalimumab in Biologic-naïve Patients With Crohn's Disease After Resolution of an Intra-abdominal Abscess: A Prospective Study From the GETAID. Clinical Gastroenterology and Hepatology. doi:10.1016/j.cgh.2023.01.013

Noor, N. M., Sousa, P., Bettenworth, D., Gomollon, F., Lobaton, T., Bossuyt, P., Casanova, M. J., Ding, N. S., Dragoni, G., Furfaro, F., van Rheenen, P. F., Chaparro, M., Gisbert, J. P., Louis, E., & Papamichael, K. (2023). ECCO Topical Review on Biological Treatment Cycles in Crohn's Disease. Journal of Crohn's and Colitis. doi:10.1093/ecco-jcc/jjad001

Bhatt, K., Meuwis, M.-A., Louis, E., Stefanuto, P.-H., & Focant, J.-F. (2023). Comprehensive insight into Colorectal Cancer metabolites by Human Serum Sample [Paper presentation]. Metabolomics 2023.

Bhatt, K., Orlando, T., Meuwis, M.-A., Louis, E., Stefanuto, P.-H., & Focant, J.-F. (2023). GC×GC-LR/HR-TOFMS for Colorectal Cancer Metabolomics and Lipidomics [Paper presentation]. SFSM2023.

Cheon, J. H., Paridaens, K., Awadhi, S. A., Begun, J., Fullarton, J. R., Louis, E., Magro, F., Marquez, J. R., Moschen, A. R., Narula, N., Rydzewska, G., Dignass, A. U., & Travis, S. P. (January 2023). The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitis. Intestinal Research, 21 (1), 161-167. doi:10.5217/ir.2022.00006

Focant, J.-F., Bhatt, K., Meuwis, M.-A., Louis, E., & Stefanuto, P.-H. (2023). Metabolomics of Colorectal Cancer for Human Serum Screening [Paper presentation]. ASMS2023.

Louis, E., Siegel, C. A., James, B., Heidenreich, S., Krucien, N., & Ghosh, S. (2023). Patients with Inflammatory Bowel Disease Have Heterogeneous Treatment Preferences That Are Largely Determined by the Avoidance of Abdominal Pain and Side Effects [P-POWER IBD Study]. Journal of Crohn's and Colitis. doi:10.1093/ecco-jcc/jjac130

Reenaers, C., GILLARD, R., Coimbra, C., GILLARD, R., Meunier, P., LECHANTEUR, C., BAUDOUX, E., BOUTAFFALA, L., Beguin, Y., & Louis, E. (2023). Clinical and MRI evolution after local injection of bone marrow-derived mesenchymal stem cells in perianal fistulae in Crohn’s disease: results from a prospective monocentric study. Journal of Crohn's and Colitis, 17, 728-737. doi:10.1093/ecco-jcc/jjac192

Vieujean, S., & Louis, E. (2023). Precision Medicine and Drug Optimization in Adults Inflammatory Bowel Disease Patients. Therapeutic Advances in Gastroenterology. doi:10.1177/17562848231173331

Gonza Quito, I. E., Goya-Jorge, E., Douny, C., Scippo, M.-L., Louis, E., & Delcenserie, V. (15 December 2022). Effect of food additives on gut microbiota of healthy donors and IBD patients [Paper presentation]. FARAH Day, Liège, Belgium.

Chevet, E., Bassal, F., Beq, S., Bonhomme, B., Boisteau, E., Calloch, J., Cazals-Hatem, D., Delom, F., Fessart, D., Evrard, S., Hrstka, R., hupp, T., Lièvre, A., Louis, E., Mariau, J., Meuwis, M.-A., Ogier-Denis, E., Paradis, V., Pernot, S., ... Vieujean, S. (2022). AGR2 protein expression in colorectal tumour epithelial compartment [letter to the editor]. Gut, 2022-328739. doi:10.1136/gutjnl-2022-328739

Valdes-Socin, H. G., Calvete, O., Benitez, J., Louis, E., & Pétrossians, P. (05 December 2022). Familial autoimmune thyrogastric syndrome: clinical, genetic and in vitro studies. Acta Clinica Belgica, 77 (sup2), 1-74. doi:10.1080/17843286.2022.2149807

Truyens, M., Lobatón, T., Ferrante, M., Bossuyt, P., Vermeire, S., Pouillon, L., Dewint, P., Cremer, A., Peeters, H., Lambrecht, G., Louis, E., Rahier, J.-F., Dewit, O., Muls, V., Holvoet, T., Vandermeulen, L., Peeters, A., Gonzales, G. B., Bos, S., ... De Vos, M. (November 2022). Effect of 5-Hydroxytryptophan on Fatigue in Quiescent Inflammatory Bowel Disease: A Randomized Controlled Trial. Gastroenterology, 163 (5), 1294-1305.e3. doi:10.1053/j.gastro.2022.07.052

Peyrin-Biroulet, L., Ghosh, S., Lee, S. D., Lee, W.-J., Griffith, J., Wallace, K., Berg, S., Liao, X., Panes, J., Loftus, E. V. J., & Louis, E. (2022). Effect of risankizumab on health-related quality of life in patients with Crohn's disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trials. Alimentary Pharmacology and Therapeutics. doi:10.1111/apt.17242

CORE-IBD Collaborators, Ma, C., Hanzel, J., Panaccione, R., Sandborn, W. J., D'Haens, G. R., Ahuja, V., Atreya, R., Bernstein, C. N., Bossuyt, P., Bressler, B., Bryant, R. V., Cohen, B., Colombel, J.-F., Danese, S., Dignass, A., Dubinsky, M. C., Fleshner, P. R., Gearry, R. B., ... Jairath, V. (October 2022). CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease. Gastroenterology, 163 (4), 950 - 964. doi:10.1053/j.gastro.2022.06.068

D'Haens, G., Panés, J., Louis, E., Lacerda, A., Zhou, Q., Liu, J., & Loftus, E. V. J. (October 2022). Upadacitinib Was Efficacious and Well-tolerated Over 30 Months in Patients With Crohn's Disease in the CELEST Extension Study. Clinical Gastroenterology and Hepatology, 20 (10), 2337-2346.e3. doi:10.1016/j.cgh.2021.12.030

Castiglione, V., Berodes, M., LUKAS, P., Louis, E., Cavalier, E., & Lutteri, L. (27 September 2022). New Faecal Calprotectin Assay by IDS: Validation and Comparison to DiaSorin Method. Diagnostics, 12 (10), 2338. doi:10.3390/diagnostics12102338

Amiot, A., Laharie, D., Malamut, G., Serrero, M., Poullenot, F., educational committee of the, G. E. T. A. I. D., Peyrin-Biroulet, L. (Other coll.), Laharie, D. (Other coll.), Bourreille, A. (Other coll.), Vuitton, L. (Other coll.), Bouguen, G. (Other coll.), Abitbol, V. (Other coll.), Amiot, A. (Other coll.), Biron, A. (Other coll.), Bourrier, A. (Other coll.), Caillo, L. (Other coll.), Fumery, M. (Other coll.), Gilletta, C. (Other coll.), Plastaras, L. (Other coll.), ... Wils, P. (Other coll.). (September 2022). Management of immune checkpoint inhibitor in patients with cancer and pre-existing inflammatory bowel disease: Recommendations from the GETAID. Digestive and Liver Disease, 54 (9), 1162-1167. doi:10.1016/j.dld.2022.06.020

International IBD Genetics Consortium, Rahmouni, S., Georges, M., & LOUIS, E. (September 2022). Large-scale sequencing identifies multiple genes and rare variants associated with Crohn's disease susceptibility. Nature Genetics, 54 (9), 1275-1283. doi:10.1101/2021.06.15.21258641

Laharie, D., D'Haens, G., Nachury, M., Lambrecht, G., Bossuyt, P., Bouhnik, Y., Louis, E., Janneke van der Woude, C., Buisson, A., Van Hootegem, P., Allez, M., Filippi, J., Brixi, H., Gilletta, C., Picon, L., Baert, F., Vermeire, S., Duveau, N., & Peyrin-Biroulet, L. (September 2022). Steroid-Free Deep Remission at One Year Does Not Prevent Crohn's Disease Progression: Long-Term Data From the TAILORIX Trial. Clinical Gastroenterology and Hepatology, 20 (9), 2074-2082. doi:10.1016/j.cgh.2021.11.030

Sazonovs, A., Stevens, C. R., Venkataraman, G. R., Yuan, K., Avila, B., Abreu, M. T., Ahmad, T., Allez, M., Ananthakrishnan, A. N., Atzmon, G., Baras, A., Barrett, J. C., Barzilai, N., Beaugerie, L., Beecham, A., Bernstein, C. N., Bitton, A., Bokemeyer, B., Chan, A., ... Daly, M. J. (2022). Large-scale sequencing identifies multiple genes and rare variants associated with Crohn’s disease susceptibility. Nature Genetics. doi:10.1038/s41588-022-01156-2

Pierre, N., Huynh-Thu, V. A., Marichal, T., Allez, M., Bouhnik, Y., Laharie, D., Bourreille, A., Colombel, J.-F., Meuwis, M.-A., Louis, E., & GETAID (Groupe d’Etude Thérapeutique des Affections Inflammatoires du tube Digestif). (2022). Distinct blood protein profiles associated with the risk of short-term and mid/long-term clinical relapse in patients with Crohn's disease stopping infliximab: when the remission state hides different types of residual disease activity. Gut, 2022-327321. doi:10.1136/gutjnl-2022-327321

Peyrin-Biroulet, L., Arkkila, P., Armuzzi, A., Danese, S., Guardiola, J., Jahnsen, J., Lees, C., Louis, E., Lukáš, M., Reinisch, W., Roblin, X., Jang, M., Byun, H. G., Kim, D.-H., Lee, S. J., & Atreya, R. (08 June 2022). Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis. BMC Gastroenterology, 22 (1), 291. doi:10.1186/s12876-022-02347-1

D'Haens, G. R., Sandborn, W. J., Loftus, E. V. J., Hanauer, S. B., Schreiber, S., Peyrin-Biroulet, L., Panaccione, R., Panés, J., Baert, F., Colombel, J.-F., Ferrante, M., Louis, E., Armuzzi, A., Zhou, Q., Goteti, V. S., Mostafa, N. M., Doan, T. T., Petersson, J., Finney-Hayward, T., ... Danese, S. (June 2022). Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results. Gastroenterology, 162 (7), 1876-1890. doi:10.1053/j.gastro.2022.01.044

Panés, J., Colombel, J.-F., D'Haens, G. R., Schreiber, S., Panaccione, R., Peyrin-Biroulet, L., Loftus, E. V. J., Danese, S., Tanida, S., Okuyama, Y., Louis, E., Armuzzi, A., Ferrante, M., Vogelsang, H., Hibi, T., Watanabe, M., Lefebvre, J., Finney-Hayward, T., Sanchez Gonzalez, Y., ... Sandborn, W. J. (June 2022). Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results. Gastroenterology, 162 (7), 1891-1910. doi:10.1053/j.gastro.2022.02.033

VIEUJEAN, S., Caron, B., Jairath, V., Benetos, A., Danese, S., LOUIS, E., & Peyrin-Biroulet, L. (22 May 2022). Is it time to include older adults in inflammatory bowel disease trials? A call for action. The Lancet Healthy Longevity, 3 (5), 356 - e366. doi:10.1016/S2666-7568(22)00060-5

Gonza Quito, I. E., Goya-Jorge, E., Douny, C., Mohring, V., Scippo, M.-L., Louis, E., & Delcenserie, V. (05 May 2022). Impact of food additives on human gut microbiota and intestinal inflammation [Poster presentation]. International Conference on Food Digestion, Cork, Ireland.

Reenaers, C., & Louis, E. (May 2022). Nouveautés dans la prise en charge des maladies inflammatoires chroniques intestinales. Revue Médicale de Liège, 77 (5-6), 323-329.

Stefanuto, P.-H., Zanella, D., Dejong, T., Massenet, T., DiGiovanni, N., GILTAY, L., HENKET, M., GUISSARD, F., SCHLEICH, F., GUIOT, J., ANDRE, B., MALAISE, M., Potjewijd, J., MEUWIS, M.-A., LOUIS, E., & Focant, J.-F. (May 2022). Recent advances in medical applications of GC×GC [Paper presentation]. HTC-17, Ghent, Belgium.

Petrov, V., Sharapov, S., Shagam, L., Nostaeva, A., Pezer, M., Li, D., Hanić, M., McGovern, D., LOUIS, E., Rahmouni, S., Lauc, G., Georges, M., & Aulchenko, Y. S. (29 April 2022). Association between human gut microbiome and N-glycan composition of total plasma proteome. Frontiers in Microbiology, 13:811922.

Dignass, A. U., Paridaens, K., Al Awadhi, S., Begun, J., Cheon, J. H., Fullarton, J. R., Louis, E., Magro, F., Marquez, J. R., Moschen, A. R., Narula, N., Rydzewska, G., & Travis, S. P. L. (April 2022). Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis. Scandinavian Journal of Gastroenterology, 57 (4), 424-431. doi:10.1080/00365521.2021.2015801

GREGOIRE, C., SERVAIS, S., WILLEMS, E., BAUDOUX, E., LECHANTEUR, C., BRIQUET, A., Bettonville, V., DETRY, O., ERPICUM, P., JOURET, F., LOUIS, E., BARON, F., & BEGUIN, Y. (April 2022). Immunothérapie cellulaire au CHU de Liège : avancées, défis et perspectives. Revue Médicale de Liège, 77 (4), 206-211.

Danese, S., Colombel, J.-F., Lukas, M., Gisbert, J. P., D'Haens, G., Hayee, B. H., Panaccione, R., Kim, H.-S., Reinisch, W., Tyrrell, H., Oh, Y. S., Tole, S., Chai, A., Chamberlain-James, K., Tang, M. T., Schreiber, S., GARDENIA Study, G., Louis, E. (Other coll.), Aboo, N. (Other coll.), ... Ziady, C. (Other coll.). (February 2022). Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. The Lancet Gastroenterology and Hepatology, 7 (2), 118-127. doi:10.1016/S2468-1253(21)00294-6

Louis, E., Paridaens, K., Al Awadhi, S., Begun, J., Cheon, J. H., Dignass, A. U., Magro, F., Márquez, J. R., Moschen, A. R., Narula, N., Rydzewska, G., Freddi, M. J., & Travis, S. P. (February 2022). Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis. BMJ Open Gastroenterology, 9 (1). doi:10.1136/bmjgast-2021-000853

Peyrin-Biroulet, L., Hart, A., Bossuyt, P., Long, M., Allez, M., Juillerat, P., Armuzzi, A., Loftus, E. V. J., Ostad-Saffari, E., Scalori, A., Oh, Y. S., Tole, S., Chai, A., Pulley, J., Lacey, S., Sandborn, W. J., HICKORY Study, G., Louis, E. (Other coll.), Aguilar, H. (Other coll.), ... Zeuzem, S. (Other coll.). (February 2022). Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. The Lancet Gastroenterology and Hepatology, 7 (2), 128-140. doi:10.1016/S2468-1253(21)00298-3

AMICONE, C., Marques, C. C., Reenaers, C., Van Kemseke, C., Seidel, L., & Louis, E. (2022). Early Post-Operative Endoscopy Is Associated with Lower Surgical Recurrence of Crohn's Disease: A Retrospective Study of Three Successive Cohorts. Gastroenterology Research and Practice, 2022, 6341069. doi:10.1155/2022/6341069

D'Haens, G. R., Reinisch, W., Lee, S. D., Tarabar, D., Louis, E., Kłopocka, M., Klaus, J., Schreiber, S., Il Park, D., Hébuterne, X., Nagy, P., Cataldi, F., Martin, S. W., Nayak, S., Banerjee, A., Gorelick, K. J., & Sandborn, W. J. (2022). Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn's Disease: The OPERA II Study. Inflammatory Bowel Diseases. doi:10.1093/ibd/izab215

Louis, E. (January 2022). Stopping Anti-TNF in Crohn's Disease Remitters: Pros and Cons: The Pros. Inflammatory Intestinal Diseases, 7 (1), 64-68. doi:10.1159/000520942

MOREAU, A.-C., SEIDEL, L., VIEUJEAN, S., REENAERS, C., & LOUIS, E. (January 2022). Impact clinique de la vidéocapsule endoscopique du grêle dans les saignements digestifs inexpliqués. Etude rétrospective monocentrique. Revue Médicale de Liège, 77 (1), 25-31.

Valdes-Socin, H., calvete, O., Benitez, J., Louis, E., & Pétrossians, P. (2022). Le syndrome thyro-gastrique auto-immun familial : études cliniques et génétiques. Annales d'Endocrinologie. doi:10.1016/j.ando.2022.07.088

VIEUJEAN, S., LOLY, J.-P., BOUTAFFALA, L., MEUNIER, P., REENAERS, C., BRIQUET, A., LECHANTEUR, C., BAUDOUX, E., BEGUIN, Y., & LOUIS, E. (2022). Mesenchymal Stem Cell Injection in Crohn's Disease Strictures: a phase I-II clinical study. Journal of Crohn's and Colitis, 16, 506-510. doi:10.1093/ecco-jcc/jjab154

Gonza Quito, I. E., Douny, C., Mohring, V., Scippo, M.-L., Louis, E., & Delcenserie, V. (07 October 2021). Impact of food additives on intestinal microbiota and inflammation [Poster presentation]. Conference of Food Microbiology, Brussels, Belgium.

Basbous, C., Hayette, M.-P., LEONARD, P., Louis, E., LOLY, J.-P., & Detry, O. (July 2021). Cholangite obstructive chez un patient atteint d’une hydatidose. Revue Médicale de Liège, 76 (7-8), 575-578.

Bouhuys, M., Lexmond, W. S., Dijkstra, G., Lobatón, T., Louis, E., van Biervliet, S., Groen, H., Guardiola, J., & Rheenen, P. V. (2021). Efficacy of anti-TNF dosing interval lengthening in adolescents and young adults with inflammatory bowel disease in sustained remission (FREE-study): protocol for a partially randomised patient preference trial. BMJ Open, 11 (11), 054154. doi:10.1136/bmjopen-2021-054154

D'Amico, F., Rubin, D. T., Kotze, P. G., Magro, F., Siegmund, B., Kobayashi, T., Olivera, P. A., Bossuyt, P., Pouillon, L., Louis, E., Domènech, E., Ghosh, S., Danese, S., & Peyrin-Biroulet, L. (2021). International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases. United European Gastroenterology Journal, 9 (4), 451-460. doi:10.1002/ueg2.12069

Dubinsky, M. C., Collins, R., Abreu, M. T., Jairath, V., Lewis, J. D., Lindsay, J., Merad, M., Ng, S., Panaccione, R., Panes, J., Sands, B., Siegal, C. A., Singh, S. K., Vermeire, S., Ahuja, V., Allez, M., Ananthakrishnan, A., Bemelman, W., Braun, J., ... Louis, E. (Other coll.). (2021). Challenges and Opportunities in IBD Clinical Trial Design. Gastroenterology, 161 (2), 400-404. doi:10.1053/j.gastro.2021.03.065

Ferrante, M., Feagan, B. G., Panés, J., Baert, F., Louis, E., Dewit, O., Kaser, A., Duan, W. R., Pang, Y., Lee, W.-J., Gustafson, D., Liao, X., Wallace, K., Kalabic, J., & D'Haens, G. R. (2021). Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study. Journal of Crohn's and Colitis. doi:10.1093/ecco-jcc/jjab093

Ghosh, S., Sanchez Gonzalez, Y., Zhou, W., Clark, R., Xie, W., Louis, E., Loftus, E. V. J., Panes, J., & Danese, S. (2021). Upadacitinib Treatment Improves Symptoms of Bowel Urgency and Abdominal Pain, and Correlates With Quality of Life Improvements in Patients With Moderate to Severe Ulcerative Colitis. Journal of Crohn's and Colitis. doi:10.1093/ecco-jcc/jjab099

Gomollón, F., & Louis, E. (2021). Editorial: Personalizing Treatment in IBD: Hype or Reality in 2020? Frontiers in Medicine, 8, 673991. doi:10.3389/fmed.2021.673991

Guillo, L., Peyrin-Biroulet, L., & Louis, E. (2021). Tofacitinib De-escalation Strategy in Ulcerative Colitis: Is It the End of the Story? Journal of Crohn's and Colitis, 15 (7), 1087-1088. doi:10.1093/ecco-jcc/jjab006

LABILLE, V., Louis, E., & LOLY, C. (2021). Stratégie «Watch and Wait» dans la prise en charge des adénocarcinomes du rectum. Revue Médicale de Liège, 76 (5-6), 515-518.

Monin, L., Dubois, S., REENAERS, C., VAN KEMSEKE, C., LATOUR, P., VAN DAELE, D., VIEUJEAN, S., SEIDEL, L., & Louis, E. (2021). Ustekinumab in bio-naïve and bio-failure Crohn's disease patients: Results from a « real-life » monocentric cohort. Digestive and Liver Disease. doi:10.1016/j.dld.2020.10.040

Nachury, M., Bouhnik, Y., Serrero, M., Filippi, J., Roblin, X., Kirchgesner, J., Bouguen, G., Franchimont, D., Savoye, G., Buisson, A., Louis, E., Nancey, S., Abitbol, V., Reimund, J.-M., DeWit, O., Vuitton, L., Matthieu, N., Peyrin-Biroulet, L., Gilletta, C., ... Reenaers, C. (Other coll.). (2021). Patients' real-world experience with inflammatory bowel disease: A cross-sectional survey in tertiary care centres from the GETAID group. Digestive and Liver Disease. doi:10.1016/j.dld.2020.10.020

Niemi, M., Gazon, H., JUSZCZAK, D., FADEUR, M., CAMBY, S., MEURIS, C., THYS, M., JACQUES, J., HENKET, M., BEGUIN, Y., Rahmouni, S., Lebrun, M., MOUTSCHEN, M., Misset, B., DARCIS, G., GUIOT, J., AZARZAR, S., DELLOT, P., GOFFLOT, S., ... HUYNEN, P. (Other coll.). (2021). Mapping the human genetic architecture of COVID-19. Nature, 600, 472-477. doi:10.1038/s41586-021-03767-x

Olivera, P. A., Zuily, S., Kotze, P. G., Regnault, V., Al Awadhi, S., Bossuyt, P., Gearry, R. B., Ghosh, S., Kobayashi, T., Lacolley, P., Louis, E., Magro, F., Ng, S. C., Papa, A., Raine, T., Teixeira, F. V., Rubin, D. T., Danese, S., & Peyrin-Biroulet, L. (2021). International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. Nature Reviews Gastroenterology and Hepatology, 18 (12), 857-873. doi:10.1038/s41575-021-00492-8

Parzibut, G., Henket, M., Moermans, C., Struman, I., Louis, E., Malaise, M., Louis, R., Misset, B., NJOCK, M.-S.* , & Guiot, J.*. (2021). A Blood Exosomal miRNA Signature in Acute Respiratory Distress Syndrome. Frontiers in Molecular Biosciences, 8, 640042. doi:10.3389/fmolb.2021.640042

Pauwels, R. W. M., van der Woude, C. J., Nieboer, D., Steyerberg, E. W., Casanova, M. J., Gisbert, J. P., Kennedy, N. A., Lees, C. W., Louis, E., Molnár, T., Szántó, K., Leo, E., Bots, S., Downey, R., Lukas, M., Lin, W. C., Amiot, A., Lu, C., Roblin, X., ... de Vries, A. C. (2021). Prediction of Relapse After Anti-Tumor Necrosis Factor Cessation in Crohn's Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies. Clinical Gastroenterology and Hepatology. doi:10.1016/j.cgh.2021.03.037

Peyrin-Biroulet, L., Louis, E., Loftus, E. V., Lacerda, A., Zhou, Q., Sanchez Gonzalez, Y., & Ghosh, S. (2021). Quality of Life and Work Productivity Improvements with Upadacitinib: Phase 2b Evidence from Patients with Moderate to Severe Crohn’s Disease. Advances in Therapy. doi:10.1007/s12325-021-01660-7

Pierre, N., Baiwir, D., Huynh-Thu, V. A., Mazzucchelli, G., Smargiasso, N., De Pauw, E., Bouhnik, Y., Laharie, D., Colombel, J.-F., Meuwis, M.-A., & Louis, E. (2021). Discovery of biomarker candidates associated with the risk of short-term and mid/long-term relapse after infliximab withdrawal in Crohn's patients: a proteomics-based study. Gut. doi:10.1136/gutjnl-2020-322100

Pierre, N., Huynh-Thu, V. A., Allez, M., Bouhnik, Y., Laharie, D., Bourreille, A., Colombel, J. F., Meuwis, M.-A., & Louis, E. (2021). Blood proteins related to immunoregulation or cellular junctions reveal distinct biological profiles associated with the risk of short-term versus mid/long-term relapse in Crohn’s Disease patients stopping infliximab. Journal of Crohn's and Colitis. doi:10.1093/ecco-jcc/jjab075.011

Pierre, N., Huynh-Thu, V. A., Matthieu, A., Yoram, B., David, L., Arnaud, B., Jean-Frédéric, C., Meuwis, M.-A., & Louis, E. (2021). Blood proteins linked to immune tolerance, inflammation and cellular junctions reveal a succession of pathophysiological events preceding the relapse in Crohn’s disease patients stopping infliximab [Paper presentation]. 33rd Belgian Week of Gastroenterology 2021, Belgium.

Pierre, N., Salée, C., Vieujean, S., Bequet, E., Merli, A.-M., Siegmund, B., Meuwis, M.-A., & Louis, E. (2021). Review article: distinctions between ileal and colonic Crohn's disease: from physiology to pathology. Alimentary Pharmacology and Therapeutics, 54 (6), 779-791. doi:10.1111/apt.16536

Pouillon, L., Remen, T., AMICONE, C., Louis, E., Maes, S., REENAERS, C., Germain, A., Baumann, C., Bossuyt, P., & Peyrin-Biroulet, L. (2021). Risk of Late Postoperative Recurrence of Crohn's Disease in Patients in Endoscopic Remission After Ileocecal Resection, Over 10 Years at Multiple Centers. Clinical Gastroenterology and Hepatology. doi:10.1016/j.cgh.2020.05.027

Scherer, M., Gasparoni, G., Rahmouni, S., Shashkova, T., Arnoux, M., Louis, E., Nostaeva, A., Avalos, D., Dermitzakis, E. T., Aulchenko, Y. S., Lengauer, T., Lyons, P. A., Georges, M., & Walter, J. R. (2021). Identification of tissue-specific and common methylation quantitative trait loci in healthy individuals using MAGAR. Epigenetics and Chromatin, 14 (1), 44. doi:10.1186/s13072-021-00415-6

Siegel, C. A., Melmed, G. Y., McGovern, D. P., Rai, V., Krammer, F., Rubin, D. T., Abreu, M. T., Dubinsky, M. C., & Louis, E. (Other coll.). (2021). SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting. Gut, 70 (4), 635-640. doi:10.1136/gutjnl-2020-324000

Siegel, C. A., Thompson, K. D., Walls, D., Gollins, J., Buisson, A., Olympie, A., Beaugerie, L., Colombel, J.-F., & Louis, E. (2021). Perspectives From Patients and Gastroenterologists on De-escalating Therapy for Crohn's Disease. Clinical Gastroenterology and Hepatology. doi:10.1016/j.cgh.2019.11.062

Tadbiri, S., Nachury, M., Bouhnik, Y., Serrero, M., Hébuterne, X., Roblin, X., Kirchgesner, J., Bouguen, G., Franchimont, D., Savoye, G., Buisson, A., Louis, E., Nancey, S., Abitbol, V., Reimund, J.-M., DeWit, O., Vuitton, L., Matthieu, N., Peyrin-Biroulet, L., ... Amiot, A. (2021). The IBD-disk is a reliable tool to assess the daily-life burden of patients with inflammatory bowel disease. Journal of Crohn's and Colitis. doi:10.1093/ecco-jcc/jjaa244

Tannoury, J., Nachury, M., Martins, C., Serrero, M., Filippi, J., Roblin, X., Bourrier, A., Bouguen, G., Franchimont, D., Savoye, G., Buisson, A., Louis, E., Nancey, S., Abitbol, V., Reimund, J.-M., DeWitt, O., Vuitton, L., Mathieu, N., Peyrin-Biroulet, L., ... Amiot, A. (2021). Determinants of IBD-related disability: a cross-sectional survey from the GETAID. Alimentary Pharmacology and Therapeutics, 53 (10), 1098-1107. doi:10.1111/apt.16353

Thibault, G., Paintaud, G., Sung, H. C., Lajoie, L., Louis, E., The Getaid, Desvignes, C., Watier, H., Gouilleux-Gruart, V., & Ternant, D. (2021). Association of IgG1 Antibody Clearance with FcγRIIA Polymorphism and Platelet Count in Infliximab-Treated Patients. International Journal of Molecular Sciences, 22 (11). doi:10.3390/ijms22116051

GUIOT, J., Cambier, M., Boeckx, A., HENKET, M., Nivelles, O., GESTER, F., LOUIS, E., MALAISE, M., Dequiedt, F., LOUIS, R., Struman, I.* , & NJOCK, M.-S.*. (05 August 2020). Macrophage-derived exosomes attenuate fibrosis in airway epithelial cells through delivery of antifibrotic miR-142-3p. Thorax, 75 (10), 870-881. doi:10.1136/thoraxjnl-2019-214077

Poulet, C., NJOCK, M.-S., MOERMANS, C., LOUIS, E., LOUIS, R., MALAISE, M., & GUIOT, J. (01 May 2020). Exosomal Long Non-Coding RNAs in Lung Diseases. International Journal of Molecular Sciences, 21 (10), 3580. doi:10.3390/ijms21103580

Bossuyt, P., Dreesen, E., Rimola, J., Devuysere, S., De Bruecker, Y., Vanslembrouck, R., Laurent, V., Zappa, M., Savoye-Collet, C., Pariente, B., Filippi, J., Baert, F., D'Haens, G., Laharie, D., Peyrin-Biroulet, L., Vermeire, S., & Louis, E. (Other coll.). (2020). Infliximab Exposure Associates With Radiologic Evidence of Healing in Patients With Crohn's Disease. Clinical Gastroenterology and Hepatology. doi:10.1016/j.cgh.2020.04.052

Bouhnik, Y., Louis, E., & Peyrin-Biroulet, L. (2020). Looking for Innovative Digital Solutions to Optimize Patient Recruitment in Inflammatory Bowel Disease Trials. Gastroenterology, 158 (8), 2306-2307. doi:10.1053/j.gastro.2019.11.313

Brand, E. C., Elias, S. G., Minderhoud, I. M., van der Veen, J. J., Baert, F. J., Laharie, D., Bossuyt, P., Bouhnik, Y., Buisson, A., Lambrecht, G., Louis, E., Pariente, B., Pierik, M. J., van der Woude, C. J., D'Haens, G. R. A. M., Vermeire, S., & Oldenburg, B. (2020). Systematic review and external validation of prediction models based on symptoms and biomarkers for identifying endoscopic activity in Crohn's disease. Clinical Gastroenterology and Hepatology. doi:10.1016/j.cgh.2019.12.014

Chapman, T. P., Frias Gomes, C., Louis, E., Colombel, J.-F., & Satsangi, J. (2020). Review article: withdrawal of 5-aminosalicylates in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 52 (1), 73-84. doi:10.1111/apt.15771

Chapman, T. P., Frias Gomes, C., Louis, E., Colombel, J.-F., & Satsangi, J. (2020). Letter: rationalising aminosalicylates in inflammatory bowel disease-authors' reply. Alimentary Pharmacology and Therapeutics, 52 (10), 1621. doi:10.1111/apt.16113

Chapman, T. P., Gomes, C. F., Louis, E., Colombel, J.-F., & Satsangi, J. (2020). De-escalation of immunomodulator and biological therapy in inflammatory bowel disease. The Lancet Gastroenterology and Hepatology, 5 (1), 63-79. doi:10.1016/S2468-1253(19)30186-4

de Bruyn, J. R., Bossuyt, P., Ferrante, M., West, R. L., Dijkstra, G., Witteman, B. J., Wildenberg, M., Hoentjen, F., Franchimont, D., Clasquin, E., van der Bilt, J. D., Tollens, T., Bemelman, W. A., D'Hoore, A., Duijvestein, M., D'Haens, G. R., & Louis, E. (Other coll.). (2020). High-Dose Vitamin D Does Not Prevent Postoperative Recurrence of Crohn's Disease in a Randomized Placebo-Controlled Trial. Clinical Gastroenterology and Hepatology. doi:10.1016/j.cgh.2020.05.037

DELHOUGNE, N., Allepaerts, S., GAST, P., & Louis, E. (2020). Approche critique du traitement prolonge par inhibiteurs de la pompe a protons chez les personnes agees. Revue Médicale de Liège, 75 (1), 10-16.

Di Giovanni, N., MEUWIS, M.-A., Louis, E., & Focant, J.-F. (2020). Untargeted Serum Metabolic Profiling by Comprehensive Two-Dimensional Gas Chromatography-High-Resolution Time-of-Flight Mass Spectrometry. Journal of Proteome Research, 19, 1013-1028. doi:10.1021/acs.jproteome.9b00535

Klarić, L., Tsepilov, Y. A., Stanton, C. M., Mangino, M., Sikka, T. T., Esko, T., Pakhomov, E., Salo, P., Deelen, J., McGurnaghan, S. J., Keser, T., Vučković, F., Ugrina, I., Krištić, J., Gudelj, I., Štambuk, J., Plomp, R., Pučić-Baković, M., Pavić, T., ... Hayward, C. (2020). Glycosylation of immunoglobulin G is regulated by a large network of genes pleiotropic with inflammatory diseases. Science Advances, 6 (8), 0301. doi:10.1126/sciadv.aax0301

Kouam, C., WARLING, O., VAN KEMSEKE, C., LOLY, J.-P., Louis, E., & Delwaide, J. (2020). Risques néoplasiques majorés dans la rectocolite ulcéro-hémorragique associée à la cholangite sclérosante primitive. Revue Médicale de Liège, 75 (11), 724-730.

Louis, E., Ramos-Goñi, J. M., Cuervo, J., Kopylov, U., Acosta, M. B.-D., McCartney, S., Rosenfeld, G., Bettenworth, D., Hart, A., Novak, K., Donnet, X., Easton, D., Saldaña, R., Protze, K., Tzur, E., Alperovich, G., & Casellas, F. (2020). A Qualitative Research for Defining Meaningful Attributes for the Treatment of Inflammatory Bowel Disease from the Patient Perspective. Patient. doi:10.1007/s40271-019-00407-5

Massart, I. S.* , PAULISSEN, G.* , Loumaye, A., Lause, P., Pötgens, S. A., Thibaut, M. M., Balan, E., Deldicque, L., Atfi, A., Louis, E., Gruson, D., Bindels, L. B., Meuwis, M.-A.* , & Thissen, J.-P.*. (2020). Marked Increased Production of Acute Phase Reactants by Skeletal Muscle during Cancer Cachexia. Cancers, 12 (11). doi:10.3390/cancers12113221

Moens, A., van der Woude, C. J., Julsgaard, M., Humblet, E., Sheridan, J., Baumgart, D. C., Gilletta De Saint-Joseph, C., Nancey, S., Rahier, J.-F., Bossuyt, P., Cremer, A., Dewit, S., Eriksson, C., Hoentjen, F., Krause, T., Louis, E., Macken, E., Milenkovic, Z., Nijs, J., ... Ferrante, M. (2020). Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study. Alimentary Pharmacology and Therapeutics, 51 (1), 129-138. doi:10.1111/apt.15539

Preda, C., Manuc, T., Chifulescu, A. E., Istratescu, D., Louis, E., Baicus, C., Sandra, I., Diculescu, M., Reenaers, C., VAN KEMSEKE, C., Nitescu, M., Tieranu, C., Popescu, M. C., Tugui, L., Andrei, A., Ciora, C.-A., Gheorghe, L.-S., & Manuc, M. (2020). Diet as an environmental trigger in inflammatory bowel disease: A retrospective comparative study in two European cohorts. Revista Espanola de Enfermedades Digestivas, 112 (6), 440-447. doi:10.17235/reed.2020.6552/2019

Rubin, D. T., Abreu, M. T., Rai, V., Siegel, C. A., & Louis, E. (Other coll.). (2020). Management of Patients With Crohn's Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting. Gastroenterology, 159 (1), 6-13.e6. doi:10.1053/j.gastro.2020.04.002

Sinatra, T., Grzesinski, Q., DULGHERU, R. E., Louis, E., Lancellotti, P., Maquet, P., & Radermecker, M. (2020). Grande clinique intégrée. La maladie cardiaque carcinoïde. Revue Médicale de Liège, 75 (7-8), 478-483.

ZEEVAERT, J.-B., Wain, E., Louis, E., Dorthu, L., MEURISSE, N., & Moerman, F. (2020). Abcès hépatique : rapport de cas et revue de la littérature. Revue Médicale de Liège, 75 (11), 731-737.

Bolin, K., Hertervig, E., & Louis, E. (2019). The Cost-effectiveness of Biological Therapy Cycles in the Management of Crohn's Disease. Journal of Crohn's and Colitis, 13 (10), 1323-1333. doi:10.1093/ecco-jcc/jjz063

Cremer, A., Demetter, P., De Vos, M., Rahier, J.-F., Baert, F., Moreels, T., Macken, E., Louis, E., Ferdinande, L., Fervaille, C., Dedeurwaerdere, F., BLETARD, N., Driessen, A., De Hertogh, G., Vermeire, S., & Franchimont, D. (2019). Risk of Development of More-advanced Lesions in Patients With Inflammatory Bowel Diseases and Dysplasia. Clinical Gastroenterology and Hepatology. doi:10.1016/j.cgh.2019.05.062

D'Haens, G., Kelly, O., Battat, R., Silverberg, M. S., Laharie, D., Louis, E., Savarino, E., Bodini, G., Yarur, A., Boland, B. S., Afif, W., Li, X.-J., Hale, M., Ho, J., Kondragunta, V., Huang, B., Kuy, C., Okada, L., Hester, K. D., ... Dulai, P. S. (2019). Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohn's Disease Based on Serum Levels of Proteins. Gastroenterology. doi:10.1053/j.gastro.2019.10.034

Danese, S., Hart, A., Dignass, A., Fiorino, G., Louis, E., Bonovas, S., D'Haens, G., Dotan, I., Rogler, G., Paridaens, K., & Peyrin-Biroulet, L. (2019). A multicentre prospective cohort study assessing the effectiveness of budesonide MMX(R) (Cortiment(R)(MMX(R))) for active, mild-to-moderate ulcerative colitis. United European Gastroenterology Journal, 7 (9), 1171-1182. doi:10.1177/2050640619864848

De Chambrun, G. P., Rouillon, C., Peyrin-Biroulet, L., Bouhnik, Y., Louis, E., Laharie, D., & Beaugerie, L. (2019). État des lieux sur les MICI en France: Enquête nationale du GETAID. Hépato-Gastro et Oncologie Digestive, 26 (2), 167-176. doi:10.1684/hpg.2019.1751

Dreesen, E., Baert, F., Laharie, D., Bossuyt, P., Bouhnik, Y., Buisson, A., Lambrecht, G., Louis, E., Oldenburg, B., Pariente, B., Pierik, M., van der Woude, C. J., D'Haens, G., Vermeire, S., & Gils, A. (2019). Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn's Disease. Clinical Gastroenterology and Hepatology. doi:10.1016/j.cgh.2019.05.029

Gonzalez, J. A., Vanzieleghem, T., Dumazy, A., MEURIS, C., MUTSERS, J., Christiaens, G., LECLERCQ, P., LOLY, J.-P., Louis, E., & GAST, P. (2019). On-site comparison of an enzymatic detergent and a non-enzymatic detergent-disinfectant for routine manual cleaning of flexible endoscopes. Endoscopy International Open, 7 (4), 412-E420. doi:10.1055/a-0838-4995

GUIOT, J., Struman, I., Louis, E., Louis, R., Malaise, M., & Njock, M.-S. (2019). Exosomal miRNAs in Lung Diseases: From Biologic Function to Therapeutic Targets. Journal of Clinical Medicine, 8 (9). doi:10.3390/jcm8091345

Hu, S., Cheng, M., Fan, R., Wang, Z., Wang, L., Zhang, T., Zhang, M., Louis, E., & Zhong, J. (2019). Beneficial effects of dual TORC1/2 inhibition on chronic experimental colitis. International Immunopharmacology, 70, 88-100. doi:10.1016/j.intimp.2019.02.022

Liefferinckx, C., Verstockt, B., Gils, A., Noman, M., VAN KEMSEKE, C., Macken, E., De Vos, M., Van Moerkercke, W., Rahier, J.-F., Bossuyt, P., Dutre, J., Humblet, E., Staessen, D., Peeters, H., Van Hootegem, P., Louis, E., Franchimont, D., Baert, F., & Vermeire, S. (2019). Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort Study. Journal of Crohn's and Colitis, 13 (11), 1401-1409. doi:10.1093/ecco-jcc/jjz080

LOLY, J.-P., MEURISSE, N., GAST, P., Honoré, P., Louis, E., & Meurisse, M. (2019). Alcool et complications pancréatiques. Revue Médicale de Liège, 74 (5-6), 342-348.

Louis, E. (2019). Tailoring Biologic or Immunomodulator Treatment Withdrawal in Inflammatory Bowel Disease. Frontiers in Medicine, 6, 302. doi:10.3389/fmed.2019.00302

Louis, E. (2019). Do we still need predictors of disease severity when applying a treat-to-target approach in Inflammatory Bowel Disease? Journal of Crohn's and Colitis. doi:10.1093/ecco-jcc/jjy182

Pariente, B., Hu, S., Bettenworth, D., Speca, S., Desreumaux, P., Meuwis, M.-A., Danese, S., Rieder, F., & Louis, E. (2019). Treatments for Crohn's Disease-Associated Bowel Damage: A Systematic Review. Clinical Gastroenterology and Hepatology. doi:10.1016/j.cgh.2018.06.043

Pariente, B., & Louis, E. (2019). Letter to the editor - Reply [letter to the editor]. Clinical Gastroenterology and Hepatology, 17 (12), 2623. doi:10.1016/j.cgh.2019.05.020

Pierre, N., Salee, C., MASSOT, C., BLETARD, N., Mazzucchelli, G., Smargiasso, N., Morsa, D., Baiwir, D., De Pauw, E., REENAERS, C., VAN KEMSEKE, C., LOLY, J.-P., Delvenne, P., Meuwis, M.-A., & Louis, E. (2019). Proteomics highlights common and distinct pathophysiological processes associated with ileal and colonic ulcers in Crohn's disease. Journal of Crohn's and Colitis. doi:10.1093/ecco-jcc/jjz130

Pineton de Chambrun, G., Amiot, A., Bouguen, G., Viennot, S., Altwegg, R., Louis, E., Collins, M., Fumery, M., Poullenot, F., Armengol, L., Buisson, A., Abitbol, V., Laharie, D., Seksik, P., Nancey, S., Blanc, P., Bouhnik, Y., Pariente, B., & Peyrin-Biroulet, L. (2019). Efficacy of Tumor Necrosis Factor Antagonist Treatment in Patients With Refractory Ulcerative Proctitis. Clinical Gastroenterology and Hepatology. doi:10.1016/j.cgh.2019.05.060

Sands, B. E., Sandborn, W. J., Panaccione, R., O'Brien, C. D., Zhang, H., Johanns, J., Adedokun, O. J., Li, K., Peyrin-Biroulet, L., Van Assche, G., Danese, S., Targan, S., Abreu, M. T., Hisamatsu, T., Szapary, P., Marano, C., & Louis, E. (Other coll.). (2019). Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. New England Journal of Medicine, 381 (13), 1201-1214. doi:10.1056/NEJMoa1900750

Sharapov, S. Z., Tsepilov, Y. A., Klaric, L., Mangino, M., Thareja, G., Shadrina, A. S., Simurina, M., Dagostino, C., Dmitrieva, J. B., Vilaj, M., Vuckovic, F., Pavic, T., Stambuk, J., Trbojevic-Akmacic, I., Kristic, J., Simunovic, J., Momcilovic, A., Campbell, Doherty, M., ... Aulchenko, Y. S. (2019). Defining the genetic control of human blood plasma N-glycome using genome-wide association study. Human Molecular Genetics, 28 (12), 2062-2077. doi:10.1093/hmg/ddz054

VALDES SOCIN, H. G., LECLERCQ, P., POLUS, M., Rohmer, V., Beckers, A., & Louis, E. (2019). La gastrite chronique auto-immune : une prise en charge multidisciplinaire. Revue Médicale de Liège, 74 (11), 598-605.

Varkas, G., RIBBENS, C., Louis, E., Van den Bosch, F., Lories, R., Vermeire, S., Elewaut, D., & De Vos, M. (2019). Expert consensus: practical algorithms for management of inflammatory bowel disease patients presenting with back pain or peripheral arthropathies. Alimentary Pharmacology and Therapeutics, 50 (11-12), 1204-1213. doi:10.1111/apt.15519

WARLING, O., Oger, A., LAMPROYE, A., BERNARD, V., MARTING, A., DETRY, O., Louis, E., & Delwaide, J. (2019). L'hepatite alcoolique aigue. Revue Médicale de Liège, 74 (5-6), 326-331.

Di Giovanni, N., MEUWIS, M.-A., Louis, E., & Focant, J.-F. (19 September 2018). Colorectal cancer study with GC×GC-(HR)TOFMS [Paper presentation]. Benelux Metabolomics Days, Rotterdam, Netherlands.

Pauwen, N. Y., Louis, E., Siegel, C., Colombel, J.-F., & Macq, J. (2018). Integrated Care for Crohn's Disease: a plea for the development of clinical decision support systems. Journal of Crohn's and Colitis, 1-6. doi:10.1093/ecco-jcc/jjy128

Focant, J.-F., Zanella, D., Di Giovanni, N., Meuwis, M.-A., Louis, E., Schleich, F., Louis, R., & Stefanuto, P.-H. (June 2018). GC×GC-(HR)-TOFMS for Metabolomics and Volatilomics [Paper presentation]. High-throughput MS-based proteomics and metabolomics: from cells to clinic, Novara, Italy.

Di Giovanni, N., Meuwis, M.-A., Louis, E., & Focant, J.-F. (May 2018). A new comprehensive GC×GC-HRTOFMS approach in metabolomics [Paper presentation]. 11èmes journées scientifiques du RFMF, Liege, Belgium.

Focant, J.-F., Stefanuto, P.-H., Zanella, D., Meuwis, M.-A., Louis, E., Schleich, F., & LOUIS, R. (May 2018). CONTRIBUTION OF GC×GC-(HR) TOFMS TO MEDICAL APPLICATIONS [Poster presentation]. 42nd International Symposium on Capillary Chromatography & 15th GC×GC Symposium, Riva Del Garda, Italy.

Di Giovanni, N., Cojocariu, C., Silcock, P., Meuwis, M.-A., LOUIS, E., & Focant, J.-F. (March 2018). GC-MS Orbitrap and GC×GC-(HR)TOFMS in Colorectal Cancer Metabolomics [Poster presentation]. BSMS meeting 2018, Liege, Belgium.

Merli, A.-M., MASSOT, C., BLETARD, N., QUESADA-CALVO, F., Baiwir, D., Mazzucchelli, G., Smargiasso, N., Servais, L., Oury, C., De Pauw-Gillet, M.-C., De Pauw, E., COIMBRA MARQUES, C., Colard, A., Vijverman, A., DELVENNE, P., MEUWIS, M.-A., & LOUIS, E. (February 2018). Potential diagnostic biomarkers of Ulcerative colitis-associated colorectal dysplasia [Paper presentation]. 13th congress of European Crohn's and Colitis Organisation, Vienne, Austria.

Pierre, N., REENAERS, C., VAN KEMSEKE, C., LOLY, J.-P., Mazzucchelli, G., Smargiasso, N., Baiwir, D., Morsa, D., De Pauw, E., MEUWIS, M.-A., & Louis, E. (2018). Proteomic analysis highlights divergences and convergences between ileal and colonic pathological processes involved in Crohn’s ulcers. Journal of Crohn's and Colitis. doi:10.1093/ecco-jcc/jjx180.184

VIEUJEAN, S., LOUIS, E., & REENAERS, C. (February 2018). Immunosuppressive co-treatment with Infliximab and Adalimumab is not superior than anti-TNF monotherapy to prevent treatment failure over time in ulcerative colitis [Poster presentation]. 13th Congress of ECCO, Vienna, Austria.

VIEUJEAN, S., LOUIS, E., & REENAERS, C. (February 2018). Immunosuppressive co-treatment with Infliximab and adalimumab is not superior than anti-TNF monotherapy to prevent treatment failure over time [Poster presentation]. 30th edition of Belgian Week of Gastroenterology.

VIEUJEAN, S., LOUIS, E., & REENAERS, C. (February 2018). Étude dans la vie réelle de l’association d’un traitement immunosuppresseur avec l’Infliximab et l’Adalimumab dans la colite ulcéreuse [Poster presentation]. Journées Francophones d'Hépato-gastroentérologie et d'Oncologie Digestive.

Merli, A.-M., MASSOT, C., BLETARD, N., QUESADA-CALVO, F., Baiwir, D., Mazzucchelli, G., Smargiasso, N., Servais, L., Oury, C., De Pauw-Gillet, M.-C., De Pauw, E., COIMBRA MARQUES, C., Colard, A., Vijverman, A., DELVENNE, P., MEUWIS, M.-A., & LOUIS, E. (27 January 2018). Potential diagnostic biomarkers of Ulcerative Colitis-associated colorectal dysplasia [Poster presentation]. Belgian Association for Cancer Research Annual Meeting 2018, Liège, Belgium.

Bossuyt, P., Baert, F., D'Heygere, F., Nakad, A., REENAERS, C., Fontaine, F., Franchimont, D., Dewit, O., Van Hootegem, P., Vanden Branden, S., Lambrecht, G., Ferrante, M., & Louis, E. (Other coll.). (2018). Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART Cohort. Inflammatory Bowel Diseases. doi:10.1093/ibd/izy219

Bossuyt, P., Louis, E., Mary, J.-Y., Vermeire, S., & Bouhnik, Y. (2018). Defining Endoscopic Remission in Ileocolonic Crohn's Disease: Let's Start from Scratch. Journal of Crohn's and Colitis, 12 (10), 1245-1248. doi:10.1093/ecco-jcc/jjy097

Bouhnik, Y., Carbonnel, F., Laharie, D., Stefanescu, C., Hebuterne, X., Abitbol, V., Nachury, M., Brixi, H., Bourreille, A., Picon, L., Bourrier, A., Allez, M., Peyrin-Biroulet, L., Moreau, J., Savoye, G., Fumery, M., Nancey, S., Roblin, X., Altwegg, R., ... Mary, J.-Y. (2018). Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study. Gut. doi:10.1136/gutjnl-2016-312581

Costanza, B., Turtoi, A., Bellahcene, A., Hirano, T., Peulen, O., Blomme, A., Hennequiere, J., MUTIJIMA NZARAMBA, E., Boniver, J., Meuwis, M.-A., JOSSE, C., KOOPMANSCH, B., SEGERS, K., Yokobori, T., Fahmy, K., Thiry, M., COIMBRA MARQUES, C., Garbacki, N., Colige, A., ... Castronovo, V. (2018). Innovative methodology for the identification of soluble biomarkers in fresh tissues. Oncotarget, 9 (12), 10665-10680. doi:10.18632/oncotarget.24366

D'Haens, G., Vermeire, S., Lambrecht, G., Baert, F., Bossuyt, P., Pariente, B., Buisson, A., Bouhnik, Y., Filippi, J., Vander Woude, J., Van Hootegem, P., Moreau, J., Louis, E., Franchimont, D., De Vos, M., Mana, F., Peyrin-Biroulet, L., Brixi, H., Allez, M., ... Laharie, D. (2018). Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease. Gastroenterology, 154 (5), 1343-1351.e1. doi:10.1053/j.gastro.2018.01.004

DE FLINES, J., Louis, E., & Paquot, N. (2018). Vignette diagnostique de l'etudiant. Exploration d'un syndrome de malabsorption digestive. Revue Médicale de Liège, 73 (10), 526-532.

De Vos, M., Dhooghe, B., Vermeire, S., Louis, E., Mana, F., Elewaut, A., Bossuyt, P., Baert, F., REENAERS, C., Van Gossum, M., Macken, E., Ferrante, M., Hindryckx, P., Dewit, O., Holvoet, T., & Franchimont, D. (2018). Efficacy of vedolizumab for induction of clinical response and remission in patients with moderate to severe inflammatory bowel disease who failed at least two TNF antagonists. United European Gastroenterology Journal, 6 (3), 439-445. doi:10.1177/2050640617722310

DELHOUGNE, N., COLARD, A., & Louis, E. (2018). Maladies inflammatoires chroniques de l'intestin et phenomenes thromboemboliques veineux. Revue Médicale de Liège, 73 (9), 462-467.

Doherty, G., Katsanos, K. H., Burisch, J., Allez, M., Papamichael, K., Stallmach, A., Mao, R., Berset, I. P., Gisbert, J. P., Sebastian, S., Kierkus, J., Lopetuso, L., Szymanska, E., & Louis, E. (2018). European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal ('Exit Strategies') in Inflammatory Bowel Disease. Journal of Crohn's and Colitis. doi:10.1093/ecco-jcc/jjx101

Feagan, B. G., Panes, J., Ferrante, M., Kaser, A., D'Haens, G. R., Sandborn, W. J., Louis, E., Neurath, M. F., Franchimont, D., Dewit, O., Seidler, U., Kim, K.-J., Selinger, C., Padula, S. J., Herichova, I., Robinson, A. M., Wallace, K., Zhao, J., Minocha, M., ... Bocher, W. O. (2018). Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study. The Lancet Gastroenterology and Hepatology, 3 (10), 671-680. doi:10.1016/S2468-1253(18)30233-4

Forster, C., VANHAUDENHUYSE, A., GAST, P., Louis, E., HICK, G., Brichant, J.-F., & Joris, J. (2018). Intravenous infusion of lidocaine significantly reduces propofol dose for colonoscopy: a randomised placebo-controlled study. British Journal of Anaesthesia, 121 (5), 1059-1064. doi:10.1016/j.bja.2018.06.019

Franchimont, D., Ferrante, M., Louis, E., De Vos, M., Dewit, O., Van Hootegem, P., Moreels, T., Liefferinckx, C., Bossuyt, P., Baert, F., Rahier, J.-F., & Vermeire, S. (2018). Belgian IBD research group (BIRD) position statement 2017 on the use of biosimilars in inflammatory bowel diseases (IBD). Acta Gastro-Enterologica Belgica, 81 (1), 49-53.

Gagnière, C., Bourrier, A., Seksik, P., Gornet, J.-M., DeWit, O., Nancey, S., Altwegg, R., Abitbol, V., Laharie, D., REENAERS, C., Buisson, A., Pariente, B., Viennot, S., Vuitton, L., Stefanescu, C., Marteau, P., Bouguen, G., Cosnes, J., Amiot, A., ... Louis, E. (Other coll.). (2018). Risk of serious infection in healthcare workers with inflammatory bowel disease: a case-control study of the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID). Alimentary Pharmacology and Therapeutics, 48 (7), 713-722. doi:10.1111/apt.14926

Laharie, D., Bourreille, A., Branche, J., Allez, M., Bouhnik, Y., Filippi, J., Zerbib, F., Savoye, G., Vuitton, L., Moureau, J., Amiot, A., Cosnes, J., Ricart, E., Dewit, O., Lopez-Sanroman, A., Fumery, M., Carbonnel, F., Bommelaer, G., Coffin, B., ... Louis, E. (2018). Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab. Gut. doi:10.1136/gutjnl-2016-313060

Lorenzo, D., Maire, F., Stefanescu, C., Gornet, J.-M., Seksik, P., Serrero, M., Bournet, B., Marteau, P., Amiot, A., Laharie, D., Trang, C., Coffin, B., Bellaiche, G., Cadiot, G., Reenaers, C., Racine, A., Viennot, S., Pauwels, A., Bouguen, G., ... Viennot, S. (Other coll.). (January 2018). Features of Autoimmune Pancreatitis Associated With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 16 (1), 59-67. doi:10.1016/j.cgh.2017.07.033

Louis, E. (2018). Stopping Biologics in IBD-What Is the Evidence? Inflammatory Bowel Diseases, 24 (4), 725-731. doi:10.1093/ibd/izx098

Louis, E., Reinisch, W., Schwartz, D. A., Lofberg, R., Robinson, A. M., Berg, S., Wang, A. W., Maa, J.-F., Huang, B., & Pappalardo, B. (2018). Adalimumab Reduces Extraintestinal Manifestations in Patients with Crohn's Disease: A Pooled Analysis of 11 Clinical Studies. Advances in Therapy, 35 (4), 563-576. doi:10.1007/s12325-018-0678-0

Merli, A.-M., MASSOT, C., BLETARD, N., QUESADA-CALVO, F., Baiwir, D., Mazzucchelli, G., Smargiasso, N., Servais, L., Oury, C., De Pauw-Gillet, M.-C., De Pauw, E., COIMBRA MARQUES, C., Colard, A., Vijverman, A., DELVENNE, P., MEUWIS, M.-A., & LOUIS, E. (2018). Potential diagnostic biomarkers of Ulcerative colitis-associated colorectal dysplasia. Acta Gastro-Enterologica Belgica.

Momozawa, Y., Dmitrieva, J. B., Theatre, E., Deffontaine, V., Rahmouni, S., Charloteaux, B., Crins, F., Elansary, M., Gori, A.-S., LECUT, C., Mariman, R., Mni, M., Oury, C., Altukhov, I., Alexeev, D., Aulchenko, Y., Amininejad, L., van der Meulen-de Jong, A. E., van der Woude, C. J., ... Georges, M. (2018). IBD risk loci are enriched in multigenic regulatory modules encompassing causative genes. Nature Communications. doi:10.1038/s41467-018-04365-8

Paulissen, G., de Walque, R., Bindels, L., Delzenne, N., Thissen, J.-P., Meuwis, M.-A., & Louis, E. (2018). Identification of new pathways driving muscle atrophy and biomarkers reflecting muscle atrophy in cancer cachexia. Acta Gastro-Enterologica Belgica.

Peeters, H., Louis, E., Baert, F., Dewit, O., Coche, J. C., Ferrante, M., Lambrecht, G., Colard, A., Van Gossum, A., Bossuyt, P., Moreels, T., Vander Cruyssen, B., Gils, A., & De Vos, M. (2018). Efficacy of switching to infliximab in patients with Crohn's disease with loss of response to adalimumab. Acta Gastro-Enterologica Belgica, 81 (1), 15-21.

REENAERS, C., Mary, J.-Y., Nachury, M., Bouhnik, Y., Laharie, D., Allez, M., Fumery, M., Amiot, A., Savoye, G., Altwegg, R., Devos, M., Malamut, G., Bourreille, A., Flourie, B., Marteau, P., Vuitton, L., Coffin, B., Viennot, S., Lambert, J., ... Louis, E. (2018). Outcomes 7 Years After Infliximab Withdrawal for Patients With Crohn's Disease in Sustained Remission. Clinical Gastroenterology and Hepatology. doi:10.1016/j.cgh.2017.09.061

Sandborn, W. J., Lee, S. D., Tarabar, D., Louis, E., Klopocka, M., Klaus, J., Reinisch, W., Hebuterne, X., Park, D.-I., Schreiber, S., Nayak, S., Ahmad, A., Banerjee, A., Brown, L. S., Cataldi, F., Gorelick, K. J., Cheng, J. B., Hassan-Zahraee, M., Clare, R., & D'Haens, G. R. (2018). Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study. Gut. doi:10.1136/gutjnl-2016-313457

Van de Vondel, S., Baert, F., Vanden Branden, S., Amininejad, L., Dewint, P., Van Moerkercke, W., Rahier, J.-F., Hindryckx, P., Bossuyt, P., Ferrante, M., Reenaers, C., & Louis, E. (Other coll.). (2018). Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study. Inflammatory Bowel Diseases, 24 (5), 1099-1105. doi:10.1093/ibd/izx103

Vermeire, S., D'heygere, F., Nakad, A., Franchimont, D., Fontaine, F., Louis, E., Van Hootegem, P., Dewit, O., Lambrecht, G., Strubbe, B., & Baert, F. (2018). Preference for a prefilled syringe or an auto-injection device for delivering golimumab in patients with moderate-to-severe ulcerative colitis: a randomized crossover study. Patient Preference and Adherence, 12, 1193-1202. doi:10.2147/PPA.S154181

Di Giovanni, N., Cojocariu, C., Silcock, P., MEUWIS, M.-A., Louis, E., & Focant, J.-F. (December 2017). Untargeted Metabolomics of Colorectal Cancer Using GC-Orbitrap [Paper presentation]. Orbitrap user meeting, Paris, France.

Di Giovanni, N., Cojocariu, C., Silcock, P., MEUWIS, M.-A., Louis, E., & Focant, J.-F. (December 2017). GC-MS Orbitrap and GC×GC-(HR)TOFMS in colorectal cancer metabolomics [Poster presentation]. MetaboMeeting 2017, Birmingham, United Kingdom.

VIEUJEAN, S., LOUIS, E., & REENAERS, C. (October 2017). Immunosuppressive co-treatment with Infliximab and Adalimumab is not superior than anti-TNF monotherapy to prevent treatment failure over time in ulcerative colitis [Poster presentation]. 25th UEG week, Barcelona, Spain.

Di Giovanni, N., Cojocariu, C., Silcock, P., Souza, A., MEUWIS, M.-A., LOUIS, E., & Focant, J.-F. (June 2017). Untargeted serum metabolite profiling of colorectal cancer using GC-Orbitrap technology [Poster presentation]. 13th Annual Conference of the Metabolomics Society, Brisbane, Australia.

QUESADA-CALVO, F., MASSOT, C., Bertrand, V., Longuespée, R., BLETARD, N., SOMJA, J., Mazzucchelli, G., Smargiasso, N., Baiwir, D., De Pauw-Gillet, M.-C., Delvenne, P., MALAISE, M., COIMBRA MARQUES, C., POLUS, M., De Pauw, E., MEUWIS, M.-A., & Louis, E. (24 March 2017). OLFM4, KNG1 and Sec24C identified by proteomics and immunohistochemistry as potential markers of early colorectal cancer stages. Clinical Proteomics, 24 (9). doi:10.1186/s12014-017-9143-3

Bello, C., Roseth, A., Guardiola, J., REENAERS, C., Ruiz-Cerulla, A., VAN KEMSEKE, C., Arajol, C., Reinhard, C., SEIDEL, L., & Louis, E. (2017). Usability of a home-based test for the measurement of fecal calprotectin in asymptomatic IBD patients. Digestive and Liver Disease, 49 (9), 991-996. doi:10.1016/j.dld.2017.05.009

DESIR, C., COIMBRA MARQUES, C., Decker, M., REENAERS, C., VAN KEMSEKE, C., LATOUR, P., Louis, E., & Meunier, P. (2017). Comment j'explore ... la maladie de Crohn par imagerie. Revue Médicale de Liège, 72 (1), 51-56.

Feagan, B. G., Sandborn, W. J., D'Haens, G., Panes, J., Kaser, A., Ferrante, M., Louis, E., Franchimont, D., Dewit, O., Seidler, U., Kim, K.-J., Neurath, M. F., Schreiber, S., Scholl, P., Pamulapati, C., Lalovic, B., Visvanathan, S., Padula, S. J., Herichova, I., ... Bocher, W. O. (2017). Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study. The Lancet, 389 (10080), 1699-1709. doi:10.1016/S0140-6736(17)30570-6

Fodil, N., Moradin, N., Leung, V., Olivier, J.-F., Radovanovic, I., Jeyakumar, T., Flores Molina, M., McFarquhar, A., Cayrol, R., Bozec, D., Shoukry, N. H., Kubo, M., Dimitrieva, J., Louis, E., Theatre, E., Dahan, S., Momozawa, Y., Georges, M., Yeretssian, G., & Gros, P. (2017). CCDC88B is required for pathogenesis of inflammatory bowel disease. Nature Communications, 8 (1), 932. doi:10.1038/s41467-017-01381-y

Ghosh, S., Louis, E., Beaugerie, L., Bossuyt, P., Bouguen, G., Bourreille, A., Ferrante, M., Franchimont, D., Frost, K., Hebuterne, X., Marshall, J. K., O'Shea, C., Rosenfeld, G., Williams, C., & Peyrin-Biroulet, L. (2017). Development of the IBD Disk: A Visual Self-administered Tool for Assessing Disability in Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 23 (3), 333-340. doi:10.1097/MIB.0000000000001033

GREGOIRE, C., LECHANTEUR, C., BRIQUET, A., BAUDOUX, E., BARON, F., LOUIS, E., & BEGUIN, Y. (2017). Review article: mesenchymal stromal cell therapy for inflammatory bowel diseases. Alimentary Pharmacology and Therapeutics, 45, 205-221. doi:10.1111/apt.13864

GREGOIRE, C., Louis, E., BRIQUET, A., LECHANTEUR, C., BAUDOUX, E., GIET, O., Beguin, Y., & BARON, F. (2017). The role of mesenchymal stromal cells in the treatment of ulcerative colitis and Crohn’s disease. In The Biology and Therapeutic Application of Mesenchymal Cells (pp. 730-753). Hoboken, United States: John Wiley & Sons, Inc.

Huang, H.* , Fang, M.* , Jostins, L.* , Umicevic - Mirkov, M., Boucher, G., Anderson, C. A., Andersen, V., Cleynen, I., Cortes, A., Crins, F., D'Amato, M., Deffontaine, V., Dmitrieva, J. B., DOCAMPO MARTINEZ, E., Elansary, M., Farh, K. K.-H., Franke, A., Gori, A.-S., Goyette, P., ... Barrett, J. C.*. (2017). Fine-mapping inflammatory bowel disease loci to single-variant resolution. Nature, 547 (7662), 173-178. doi:10.1038/nature22969

Katsanos, K. H., Domenech, E., Rahier, J.-F., Kopylov, U., Fiorino, G., Rogler, G., Louis, E., & Ben-Horin, S. (2017). Making a Case for Case Reports: The ECCO-CONFER Viewpoint on Investigating Rare Events in a Medical World Reigned by Group-comparative Statistics. Journal of Crohn's and Colitis. doi:10.1093/ecco-jcc/jjw131

Martelli, L., Colard, A., Fontaine, F., Deflandre, J., Bastens, B., & Louis, E. (2017). Evaluation of the efficacy of octreotide LAR in the treatment of Crohn's disease associated refractory diarrhea. Scandinavian Journal of Gastroenterology, 52 (5), 564-569. doi:10.1080/00365521.2017.1284893

Michetti, P., Weinman, J., Mrowietz, U., Smolen, J., Peyrin-Biroulet, L., Louis, E., Schremmer, D., Tundia, N., Nurwakagari, P., & Selenko-Gebauer, N. (2017). Impact of Treatment-Related Beliefs on Medication Adherence in Immune-Mediated Inflammatory Diseases: Results of the Global ALIGN Study. Advances in Therapy, 34 (1), 91-108. doi:10.1007/s12325-016-0441-3

VAN DAELE, D., Honoré, P., COLLIGNON, J., POLUS, M., LOLY, C., MUTIJIMA NZARAMBA, E., De Roover, A., Coucke, P., Louis, E., & Martinive, P. (2017). Comment je traite... les cancers localises de l'oesophage. Etat actuel des donnees et strategie therapeutique. 2eme partie : l'interet des approches multimodales avec ou sans chirurgie. Revue Médicale de Liège, 72 (4), 168-174.

VAN DAELE, D., Honoré, P., COLLIGNON, J., POLUS, M., LOLY, C., MUTIJIMA NZARAMBA, E., De Roover, A., Coucke, P., Louis, E., & Martinive, P. (2017). Comment je traite... les cancers localises de l'oesophage. Etat actuel des donnees et strategie therapeutique. 1ere partie : le point sur les approches chirurgicales et non chirurgicales. Revue Médicale de Liège, 72 (2), 58-63.

Wauters, L., Smets, F., De Greef, E., Bontems, P., Hoffman, I., Hauser, B., Alliet, P., Arts, W., Peeters, H., Van Biervliet, S., Paquot, I., Van de Vijver, E., De Vos, M., Bossuyt, P., Rahier, J.-F., Dewit, O., Moreels, T., Franchimont, D., Muls, V., ... Veereman, G. (2017). Long-term Outcomes with Anti-TNF Therapy and Accelerated Step-up in the Prospective Pediatric Belgian Crohn's Disease Registry (BELCRO). Inflammatory Bowel Diseases, 23 (9), 1584-1591. doi:10.1097/MIB.0000000000001193

Di Giovanni, N., Meuwis, M.-A., LOUIS, E., & Focant, J.-F. (28 June 2016). In the quest of robust biomarkers for inflammatory bowel disease phenotypes using GC×GC-HRTOFMS [Paper presentation]. 12th Annual Conference of the Metabolomics Society.

Di Giovanni, N., MEUWIS, M.-A., LOUIS, E., & Focant, J.-F. (30 May 2016). Discrimination between inflammatory bowel disease (IBD) phenotypes by GC×GC-HRTOFMS [Paper presentation]. 40th International Symposium on Capillary Chromatography & 13th GC×GC Symposium, Riva Del Garda, Italy.

Pesesse, R., Stefanuto, P.-H., Bertrand, V., De Pauw-Gillet, M.-C., MEUWIS, M.-A., LOUIS, E., LOUIS, R., & Focant, J.-F. (30 May 2016). GC×GC-(HR)TOFMS in Cancer Research [Paper presentation]. 40th International Symposium on Capillary Chromatography & 13th GC×GC Symposium, Riva Del Garda, Italy.

Pesesse, R., Stefanuto, P.-H., SCHLEICH, F., MEUWIS, M.-A., LOUIS, E., LOUIS, R., & Focant, J.-F. (30 May 2016). Investigation of the possible effect of sampling on human exhaled breath sample integrity [Poster presentation]. 40th International Symposium on Capillary Chromatography & 13th GC×GC Symposium, Riva Del Garda, Italy.

Pesesse, R., Stefanuto, P.-H., SCHLEICH, F., MEUWIS, M.-A., Louis, E., Louis, R., & Focant, J.-F. (28 January 2016). Characterization of human exhaled breath for non-invasive detection of diseases by GC×GC-TOFMS [Paper presentation]. 14th International Symposium on Hyphenated Techniques in Chromatography and Separation Technology, Ghent, Belgium.

Boschetti, G., Nancey, S., Daniel, F., Pariente, B., Lerebours, E., Duclos, B., Bourreille, A., Cadiot, G., Fumery, M., Moreau, J., Marteau, P., Bouhnik, Y., Louis, E., & Flourie, B. (2016). Costs of Crohn's Disease According to Severity States in France: A Prospective Observational Study and Statistical Modeling over 10 Years. Inflammatory Bowel Diseases, 22 (12), 2924-2932. doi:10.1097/MIB.0000000000000967

Bourseau, S., Meunier, P., COIMBRA MARQUES, C., & Louis, E. (2016). LA MALADIE DE CROHN STENOSANTE: Presentation clinique, diagnostic et modalites de traitement. Revue Médicale de Liège, 71 (4), 178-83.

Carbonnel, F., Colombel, J. F., Filippi, J., Katsanos, K. H., Peyrin-Biroulet, L., Allez, M., Nachury, M., Novacek, G., Danese, S., Abitbol, V., Bossa, F., Moreau, J., Bommelaer, G., Bourreille, A., Fumery, M., Roblin, X., Reinisch, W., Bouhnik, Y., Brixi, H., ... Laharie, D. (2016). Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis. Gastroenterology, 150 (2), 380-8.e4. doi:10.1053/j.gastro.2015.10.050

Cleynen, I., Boucher, G., Jostins, L., Schumm, L. P., Zeissig, S., Ahmad, T., Andersen, V., Andrews, J. M., Annese, V., Brand, S. L., Brant, S. R., Cho, J. H., Daly, M. J., Dubinsky, M., Duerr, R. H., Ferguson, L. R., Franke, A., Gearry, R., Goyette, P., ... Louis, E. (Other coll.). (2016). Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. The Lancet. doi:10.1016/s0140-6736(15)00465-1

Danese, S., Hart, A., Dignass, A., Louis, E., D'Haens, G., Dotan, I., Rogler, G., D'Agay, L., Iannacone, C., & Peyrin-Biroulet, L. (2016). Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study. BMJ Open Gastroenterology, 3 (1), 000092. doi:10.1136/bmjgast-2016-000092

De Greef, E., Hoffman, I., Smets, F., Van Biervliet, S., Bontems, P., Hauser, B., Paquot, I., Alliet, P., Arts, W., Dewit, O., De Vos, M., Baert, F., Bossuyt, P., Rahier, J.-F., Franchimont, D., Vermeire, S., Fontaine, F., Louis, E., Coche, J. C., & Veereman, G. (2016). Paediatric Crohn Disease: Disease Activity and Growth in the BELCRO Cohort After 3 Years Follow-up. Journal of Pediatric Gastroenterology and Nutrition, 63 (2), 253-8. doi:10.1097/MPG.0000000000001132

Dumont, R., LOLY, J.-P., DELWAIDE, J., & LOUIS, E. (2016). La maladie de Rendu-Osler: une cause rare d'encéphalopathie ammoniacale. Revue Médicale de Liège, 71 (2), 83-89.

MALAISE, O., RELIC, B., Charlier, E., Zeddou, M., NEUVILLE, S., Deroyer, C., Gillet, P., Louis, E., Malaise, M., & DE SENY, D. (2016). Glucocorticoid-induced leucine zipper (GILZ) is involved in glucocorticoid-induced and mineralocorticoid-induced leptin production by osteoarthritis synovial fibroblasts. Arthritis Research and Therapy, 18 (1), 219. doi:10.1186/s13075-016-1119-6

Marteau, P., Laharie, D., Colombel, J.-F., Martin, L., Coevoet, H., Allez, M., Cadiot, G., Bourreille, A., Carbonnel, F., Bouhnik, Y., Coffin, B., Duclos, B., Dupas, J. L., Moreau, J., Louis, E., & Mary, J.-Y. (2016). Interobserver Variation Study of the Rutgeerts Score to Assess Endoscopic Recurrence after Surgery for Crohn's Disease. Journal of Crohn's and Colitis, 10 (9), 1001-5. doi:10.1093/ecco-jcc/jjw082

Peyrin-Biroulet, L., Salleron, J., Filippi, J., REENAERS, C., Antunes, O., Filipe, V., Louis, E., Hebuterne, X., & Roblin, X. (2016). Anti-TNF Monotherapy for Crohn's Disease: a 13-year Multicentre Experience. Journal of Crohn's and Colitis, 10 (5), 516-24. doi:10.1093/ecco-jcc/jjw008

REENAERS, C., Pirard, C., VAN KEMSEKE, C., LATOUR, P., Belaiche, J., & Louis, E. (2016). Long-term evolution and predictive factors of mild inflammatory bowel disease. Scandinavian Journal of Gastroenterology, 51 (6), 712-9. doi:10.3109/00365521.2015.1128965

Regueiro, M., Feagan, B. G., Zou, B., Johanns, J., Blank, M. A., Chevrier, M., Plevy, S., Popp, J., Cornillie, F. J., Lukas, M., Danese, S., Gionchetti, P., Hanauer, S. B., Reinisch, W., Sandborn, W. J., Sorrentino, D., Rutgeerts, P., & Louis, E. (2016). Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. Gastroenterology, 150 (7), 1568-78. doi:10.1053/j.gastro.2016.02.072

Satsangi, J., Kitten, O., CHAVEZ, V., Kalla, R., Prel, N., Meuwis, M.-A., Scott, S., Bonetti, I., Ventham, N. T., & Louis, E. (2016). How to Apply for and Secure EU Funding for Collaborative IBD Research Projects. Journal of Crohn's and Colitis, 10 (3), 363-70. doi:10.1093/ecco-jcc/jjv237

Baiwir, D., Mazzucchelli, G., Smargiasso, N., QUESADA CALVO, F., De Pauw, E., MALAISE, M., Louis, E., & MEUWIS, M.-A. (December 2015). Comparison of serum fractionation methods by data independent label-free proteomics. EuPA Open Proteomics, 9, 14-22. doi:10.1016/j.euprot.2015.07.009

Sid, S., LUTTERI, L., BEGUIN, Y., Louis, E., Beckers, A., & VALDES SOCIN, H. G. (2015). Familial thyrogastric autoimmune syndrome : a study of 22 kindreds. In Abstract book - 20th Annual Congress of the Belgian Society of Internal Medicine.

Senéjoux, A., Siproudhis, L., Abramowitz, L., Munoz-Bongrand, N., Desseaux, K., Bouguen, G., Bourreille, A., Dewit, O., Stefanescu, C., Vernier, G., Louis, E., Grimaud, J. C., Godart, B., Savoye, G., Hebuterne, X., Bauer, P., Nachury, M., Laharie, D., Chevret, S., ... GETAID. (2015). Fistula plug in fistulising ano-perineal Crohn's disease: a randomised controlled trial. Journal of Crohn's and Colitis. doi:10.1093/ecco-jcc/jjv162

VALDES SOCIN, H. G., MESUREUR, T., POLUS, M., DELWAIDE, J., Louis, E., LUTTERI, L., & Beckers, A. (2015). Syndrome thyrogastrique autoimmun (STGA) : la gastrite auto-immune isolée (GAI) et celle associée à Helicobacter (Hp) ont des caractéristiques anatomocliniques différentes. In Abstract book - Annales d'Endocrinologie - 32ème Congrès de la Société Française d'Endocrinologie.

Louis, E., Dotan, I., Ghosh, S., Mlynarsky, L., REENAERS, C., & Schreiber, S. (2015). Optimising the Inflammatory Bowel Disease Unit to Improve Quality Of Care: Expert Recommandations. Journal of Crohn's and Colitis. doi:10.1093/ecco-jcc/jjv085

Louis, E. (2015). Fecal calprotectin: towards a standarized use for inflammatory bowel disease management in routine practice. Journal of Crohn's and Colitis. doi:10.1093/ecco-jcc/jju012

Louis, E., REENAERS, C., VAN KEMSEKE, C., LATOUR, P., BELAICHE, J., MEUNIER, P., & COIMBRA MARQUES, C. (2015). De l'"Evidence-based Medecine" à la médecine personnalisée dans la maladie de Crohn. Revue Médicale de Liège, 70 (5-6), 316-320.

Reinisch, W.* , Louis, E.* , & Danese, S.*. (2015). The scientific and regulatory rationale for indication extrapolation: A case study based on the infliximab biosimilar CT-P13. Expert Review of Gastroenterology and Hepatology, 9, 17-S26. doi:10.1586/17474124.2015.1091306

Schreiber, S., Panés, J., Louis, E., Holley, D., Buch, M., & Paridaens, K. (2015). Perception gaps between patients with ulcerative colitis and healthcare professionals: An online survey. South African Gastroenterology Review, 13 (1), 7-15.

Torres, J., Boyapati, R. K., Kennedy, N. A., Louis, E., Colombel, J.-F., & Satsangi, J. (2015). Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease. Gastroenterology, 149 (7), 1716-1730. doi:10.1053/j.gastro.2015.08.055

VAN DAELE, D., Martinive, P., LOLY, C., POLUS, M., COLLIGNON, J., GAST, P., Louis, E., & Van Laethem, J.-L. (2015). COMMENT JE TRAITE ... Point de vue critique sur l'approche actuelle du cancer du pancreas localisé. Revue Médicale de Liège, 70 (11), 540-5.

Van Kemseke, C., Louis, E., & REENAERS, C. (2015). LE MEDICAMENT DU MOIS. Vedolizumab (Entyvio(R)), nouveau traitement des maladies inflammatoires intestinales. Revue Médicale de Liège, 70 (11), 575-82.

Vermeire, S., Louis, E., Dewit, O., Franchimont, D., Moreels, T., Ferrante, M., RAHIER, J.-F., Van Hootegem, P., De Vos, M., Mana, F., & Baert, F. (2015). Clinical and scientific aspects related to biosimilars in inflammatory bowel diseases (IBD): position document of the Belgian IBD Research & Development Group (BIRD). Acta Gastro-Enterologica Belgica, 78, 26-29.

MEUWIS, M.-A., Baiwir, D., Mazzucchelli, G., Smargiasso, N., Quesada-Calvo, F., MALAISE, M., De Pauw, E., The GETAID, & LOUIS, E. (06 October 2014). Potential Proteomic Biomarkers Associated To Mucosal Healing In Crohn’s Disease [Poster presentation]. HUPO2014, Madrid, Spain.

Warling, O., BOVY, C., COIMBRA MARQUES, C., Noterdaeme, T., DELWAIDE, J., & LOUIS, E. (28 April 2014). Overlap syndrome consisting of PSC-AIH with concomitant presence of a membranous glomerulonephritis and ulcerative colitis. World Journal of Gastroenterology, 20 (16), 4811-4816. doi:10.3748/wjg.v20.i16.4811

Tack, J., LOUIS, E., Persy, V., & Urbain, D. (March 2014). Utilisation optimale des inhibiteurs de la pompe à protons dans le cadre des soins primaires. Revue Médicale de Liège, 69 (3), 139-145.

Louis, E. (2014). Diagnostic differentiel d'une diarrhee chronique. Revue Médicale de Liège, 69 (1), 51-6.

Smargiasso, N., Mazzucchelli, G., Baiwir, D., LOUIS, E., Quesada-Calvo, F., MEUWIS, M.-A., & De Pauw, E. (2014). Data dependent versus Data independent acquisition applied to samples with different protein dynamic range [Poster presentation]. 13th Human Proteome Organization World Congress.

LEDOUBLE, V., BECK, E., PETERS, P., LAMPROYE, A., & Louis, E. (2013). Thrombose portale étendue chez un patient sous anti-vitamine K. Revue Médicale de Liège, (68(7-8)), 382-6.

Benitez, J.-M., Meuwis, M.-A., REENAERS, C., VAN KEMSEKE, C., Meunier, P., & Louis, E. (2013). Role of endoscopy, cross-sectional imaging and biomarkers in Crohn's disease monitoring. Gut, 62 (12), 1806-16. doi:10.1136/gutjnl-2012-303957

Beyaert, R., Beaugerie, L., Van Assche, G., Brochez, L., Renauld, J.-C., Viguier, M., Cocquyt, V., JERUSALEM, G., Machiels, J.-P., Prenen, H., Masson, P., Louis, E., & De Keyser, F. (2013). Cancer risk in immune-mediated inflammatory diseases (IMID). Molecular Cancer, 12 (1), 98. doi:10.1186/1476-4598-12-98

De Greef, E., Mahachie John, J., Hoffman, I., Smets, F., Van Biervliet, S., Scaillon, M., Hauser, B., Paquot, I., Alliet, P., Arts, W., Dewit, O., Peeters, H., Baert, F., D'Haens, G., Rahier, J.-F., Etienne, I., Bauraind, O., Van Gossum, A., Vermeire, S., ... Veereman, G. (2013). Profile of pediatric Crohn's disease in Belgium. Journal of Crohn's and Colitis, 7 (11), 588-98. doi:10.1016/j.crohns.2013.04.016

Louis, E. (2013). Strategic use of immunosuppressants and anti-TNF in inflammatory bowel disease. Digestive Diseases, 31 (2), 207-12. doi:10.1159/000353370

Papay, P., Ignjatovic, A., Karmiris, K., Amarante, H., Milheller, P., Feagan, B., D'Haens, G., Marteau, P., Reinisch, W., Sturm, A., Steinwurz, F., Egan, L., Panes, J., Louis, E., Colombel, J.-F., & Panaccione, R. (2013). Optimising monitoring in the management of Crohn's disease: a physician's perspective. Journal of Crohn's and Colitis, 7 (8), 653-69. doi:10.1016/j.crohns.2013.02.005

VALDES SOCIN, H. G., LUTTERI, L., CAVALIER, E., POLUS, M., LOUIS, E., & BECKERS, A. (2013). le syndrome auto-immun thyrogastrique: ses effets sur les micronutriments et la tumorigénèse gastrique. Revue Médicale de Liège.

Louis, E., REENAERS, C., Meuwis, M.-A., VAN KEMSEKE, C., LATOUR, P., CHAPELIER, N., WERTZ, S., COIMBRA MARQUES, C., MEUNIER, P., & Belaiche, J. (March 2012). Quinze ans d'anti-TNF dans la maladie de Crohn: comment tirer le meilleur de cette revolution therapeutique? Revue Médicale de Liège, 67 Spec No, 8-13.

Colombel, J.-F., Louis, E., Peyrin-Biroulet, L., Sandborn, W. J., & Panaccione, R. (2012). Deep remission: A new concept? Digestive Diseases. doi:10.1159/000342732

Desselle, F., VERSET, G., POLUS, M., Louis, E., & VAN DAELE, D. (2012). Le syndrome de Lynch et l'instabilité des microsatellites : revue de littérature. Revue Médicale de Liège, 67 (12), 638-642.

Lecat, A., Di Valentin, E., Somja, J., Jourdan, S., Fillet, M., Kufer, T., Habraken, Y., Sadzot-Delvaux, C., Louis, E., Delvenne, P., Piette, J., & Legrand-Poels, S. (2012). The c-jun N-terminal Kinase (JNK)-binding Protein (JNKBP1) Acts as a Negative Regulator of NOD2 Protein Signaling by Inhibiting Its Oligomerization Process. Journal of Biological Chemistry, 287 (35), 29213-26. doi:10.1074/jbc.M112.355545

LOUIS, E. (2012). Epidemiology of the transition from early to late Crohn's disease. Digestive Diseases, 30 (4), 376-9. doi:10.1159/000338129

Louis, E., VAN KEMSEKE, C., LATOUR, P., Belaiche, J., & REENAERS, C. (2012). Genetique et environnement dans les maladies inflammatoires chroniques de l'intestin. Revue Médicale de Liège, 67 (5-6), 298-304.

LOUIS, R., SCHLEICH, F., Corhay, J.-L., & Louis, E. (2012). L'asthme: une maladie complexe mettant en jeu facteurs environnementaux et terrain genetique. Revue Médicale de Liège, 67 (5-6), 286-91.

REENAERS, C., LOUIS, E., Belaiche, J., Seidel, L., Keshav, S., & Travis, S. (2012). Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab? Alimentary Pharmacology and Therapeutics, 36 (11-12), 1040-8. doi:10.1111/apt.12076

Rivas, M. A., Beaudoin, M., Gardet, A., Stevens, C., Sharma, Y., Zhang, C. K., Boucher, G., Ripke, S., Ellinghaus, D., Burtt, N., Fennell, T., Kirby, A., Latiano, A., Goyette, P., Green, T., Halfvarson, J., Haritunians, T., Korn, J. M., Kuruvilla, F., ... LOUIS, E. (Other coll.). (2012). Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. Nature Genetics, 43 (11), 1066-73. doi:10.1038/ng.952

Schreiber, S., Panes, J., LOUIS, E., Holley, D., Buch, M., & Paridaens, K. (2012). Perception gaps between patients with ulcerative colitis and healthcare professionals: an online survey. BMC Gastroenterology, 12 (1), 108. doi:10.1186/1471-230X-12-108

Vermeire, S., Carbonnel, F., Coulie, P., Geenen, V., Hazes, J. M. W., Masson, P., de Keyser, F., & LOUIS, E. (2012). Management of inflammatory bowel disease in pregnancy. Journal of Crohn's and Colitis, 6 (8), 811-23. doi:10.1016/j.crohns.2012.04.009

Hazes, J. M. W., Coulie, P. G., Geenen, V., Vermeire, S., Carbonnel, F., LOUIS, E., Masson, P., & De Keyser, F. (2011). Rheumatoid arthritis and pregnancy: evolution of disease activity and pathophysiological considerations for drug use. Rheumatology. doi:10.1093/rheumatology/ker302

Adler, M., Piessevaux, H., Louis, E., Lamy, V., Michielsen, P., & Geubel, A. (2011). Abdominal ultrasonography by the hepato-gastroenterologist: problems, demands, solutions. Acta Gastro-Enterologica Belgica, 74 (1), 67-9.

Bello, C., Belaiche, J., Louis, E., & Reenaers, C. (2011). Evolution and predictive factors of relapse in ulcerative colitis patients treated with mesalazine after a first course of corticosteroids. Journal of Crohn's and Colitis, 5 (3), 196-202. doi:10.1016/j.crohns.2010.12.011

Binion, D. G., Louis, E., Oldenburg, B., Mulani, P., Bensimon, A. G., Yang, M., & Chao, J. (2011). Effect of adalimumab on work productivity and indirect costs in moderate to severe Crohn's disease: a meta-analysis. Canadian Journal of Gastroenterology, 25 (9), 492-6. doi:10.1155/2011/938194

DE SENY, D., Sharif, M., Fillet, M., COBRAIVILLE, G., Meuwis, M.-A., Marée, R., HAUZEUR, J.-P., Wehenkel, L., Louis, E., Merville, M.-P., Kirwan, J., Ribbens, C., & Malaise, M. (2011). Discovery and biochemical characterisation of four novel biomarkers for osteoarthritis. Annals of the Rheumatic Diseases, 70 (6), 1144-52. doi:10.1136/ard.2010.135541

Kopylov, U., Mantzaris, G. J., Katsanos, K. H., Reenaers, C., Ellul, P., Rahier, J.-F., Israeli, E., Lakatos, P. L., Fiorino, G., Cesarini, M., Tsianos, E. V., Louis, E., & Ben-Horin, S. (2011). The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab. Alimentary Pharmacology and Therapeutics, 33 (3), 349-57. doi:10.1111/j.1365-2036.2010.04523.x

Momozawa, Y., Deffontaine Deurbroeck, V., Louis, E., & Medrano, J. F. (2011). Characterization of bacteria in biopsies of colon and stools by high throughput sequencing of the V2 region of bacterial 16S rRNA gene in human. PLoS ONE, 6 (2), 16952. doi:10.1371/journal.pone.0016952

Momozawa, Y., Mni, M., Nakamura, K., Coppieters, W., Almer, S., Amininejad, L., Cleynen, I., Colombel, J.-F., de Rijk, P., Dewit, O., Finkel, Y., Gassull, M. A., Goossens, D., Laukens, D., Lemann, M., LIBIOULLE, C., O'Morain, C., Reenaers, C., Rutgeerts, P., ... Georges, M. (2011). Resequencing of positional candidates identifies low frequency IL23R coding variants protecting against inflammatory bowel disease. Nature Genetics, 43 (1), 43-7. doi:10.1038/ng.733

Rahier, J.-F., Papay, P., Salleron, J., Sebastian, S., Marzo, M., Peyrin-Biroulet, L., Garcia-Sanchez, V., Fries, W., van Asseldonk, D. P., Farkas, K., de Boer, N. K., Sipponen, T., Ellul, P., Louis, E., Peake, S. T. C., Kopylov, U., Maul, J., Makhoul, B., Fiorino, G., ... Chaparro, M. (2011). H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. Gut, 60 (4), 456-62. doi:10.1136/gut.2010.233981

TOME GARCIA, M., VALDES SOCIN, H. G., LUTTERI, L., BETEA, D., VROONEN, L., PETROSSIANS, P., Geenen, V., Louis, E., & Beckers, A. (2011). The Thyro-gastric syndrome : its prevalence, clinical, pathological and predictive factors in a prospective series of 360 patients with Hashimoto's Thyroiditis. In Abstract book - 21st Meeting of the Belgian Endocrine Society.

VALDES SOCIN, H. G., Tome, M., LUTTERI, L., Louis, E., & Beckers, A. (2011). Prevalence and prediction of gastric mucosal abnormalities in a prospective series of 50 patients with graves-Basedow disease [Poster presentation]. Belgian Internal Medicine Society, Bruxelles, Belgium.

Allez, M., Karmiris, K., Louis, E., Van Assche, G., Ben-Horin, S., Klein, A., Van der Woude, J., Baert, F., Eliakim, R., Katsanos, K., Brynskov, J., Steinwurz, F., Danese, S., Vermeire, S., Teillaud, J.-L., Lemann, M., & Chowers, Y. (2010). Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. Journal of Crohn's and Colitis, 4 (4), 355-66. doi:10.1016/j.crohns.2010.04.004

Franke, A., McGovern, D. P. B., Barrett, J. C., Wang, K., Radford-Smith, G. L., Ahmad, T., Lees, C. W., Balschun, T., Lee, J., Roberts, R., Anderson, C. A., Bis, J. C., Bumpstead, S., Ellinghaus, D., Festen, E. M., Georges, M., Green, T., Haritunians, T., Jostins, L., ... Parkes, M. (2010). Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nature Genetics, 42 (12), 1118-25. doi:10.1038/ng.717

Louis, E. (2010). Immunosuppressant combined with infliximab in Crohn's Disease: For 6 months, for 2 years, or forever? Inflammatory Bowel Diseases. doi:10.1002/ibd.21407

Rahier, J.-F., Buche, S., Peyrin-Biroulet, L., Bouhnik, Y., Duclos, B., Louis, E., Papay, P., Allez, M., Cosnes, J., Cortot, A., Laharie, D., Reimund, J.-M., Lemann, M., Delaporte, E., & Colombel, J.-F. (2010). Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clinical Gastroenterology and Hepatology, 8 (12), 1048-55. doi:10.1016/j.cgh.2010.07.022

Rahier, J.-F., Moutschen, M., Van Gompel, A., Van Ranst, M., Louis, E., Segaert, S., Masson, P., & De Keyser, F. (2010). Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology, 49 (10), 1815-27. doi:10.1093/rheumatology/keq183

Reenaers, C., Belaiche, J., & Louis, E. (2010). Should patients under long-term anti-TNF therapies be followed for tuberculosis contamination? Inflammatory Bowel Diseases, 16 (8), 1271-2. doi:10.1002/ibd.21162

Van Assche, G., Dignass, A., Panes, J., Beaugerie, L., Karagiannis, J., Allez, M., Ochsenkuhn, T., Orchard, T., Rogler, G., Louis, E., Kupcinskas, L., Mantzaris, G., Travis, S., & Stange, E. (2010). The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. Journal of Crohn's and Colitis, 4 (1), 7-27. doi:10.1016/j.crohns.2009.12.003

Louis, E., Libioulle, C., Reenaers, C., Belaiche, J., & Georges, M. (October 2009). Génomique des maladies inflammatoires intestinales. Revue Médicale de Liège, 64, 24-28.

Allez, M., Vermeire, S., Mozziconacci, N., Michetti, P., Laharie, D., Louis, E., Bigard, M.-A., Hebuterne, X., Treton, X., Kohn, A., Marteau, P., Cortot, A., Nichita, C., Vanassche, G., Rutgeerts, P., Lemann, M., & Colombel, J.-F. (2009). Efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF. Alimentary Pharmacology and Therapeutics. doi:10.1111/j.1365-2036.2009.04130.x

De Bock, M., De Seny, D., Meuwis, M.-A., Chapelle, J.-P., Louis, E., Malaise, M., Merville, M.-P., & Fillet, M. (2009). Challenges for Biomarker Discovery in Body Fluids Using SELDI-TOF-MS. Journal of Biomedicine and Biotechnology. doi:10.1155/2010/906082

De Seny, D., Ribbens, C., Cobraiville, G., Meuwis, M.-A., Marée, R., Geurts, P., Wehenkel, L., Louis, E., Merville, M.-P., Fillet, M., & Malaise, M. (2009). Protéomique par SELDI-TOF-MS des maladies inflammatoires articulaires: identification des protéines S100 comme protéines d'intérêt. Revue Médicale de Liège, 64 (Spec No), 29-35.

Imielinski, M., Baldassano, R. N., Griffiths, A., Russell, R. K., Annese, V., Dubinsky, M., Kugathasan, S., Bradfield, J. P., Walters, T. D., Sleiman, P., Kim, C. E., Muise, A., Wang, K., Glessner, J. T., Saeed, S., Zhang, H., Frackelton, E. C., Hou, C., Flory, J. H., ... Georges, M. (Other coll.). (2009). Common variants at five new loci associated with early-onset inflammatory bowel disease. Nature Genetics, 41 (12), 1335-40. doi:10.1038/ng.489

Louis, E., Belaiche, J., & Reenaers, C. (2009). Tailoring the treatment to the individual in Crohn's disease. Therapeutic Advances in Gastroenterology, 2, 239-244. doi:10.1177/1756283X09337180

Louis, E., Belaiche, J., & Reenaers, C. (2009). Anti-TNF and Crohn's Disease: When Should We Stop? Current Drug Targets, 11 (2), 148-51. doi:10.2174/138945010790309957

Louis, E., Libioulle, C., Reenaers, C., Belaiche, J., & Georges, M. (2009). Genetics of ulcerative colitis: the come-back of interleukin 10. Gut, 58 (9), 1173-6. doi:10.1136/gut.2008.169235

Piessevaux, H., De Winter, B., Louis, E., Muls, V., De Looze, D., Pelckmans, P., Deltenre, M., Urbain, D., & Tack, J. (2009). Dyspeptic symptoms in the general population: a factor and cluster analysis of symptom groupings. Neurogastroenterology and Motility, 21 (4), 378-88. doi:10.1111/j.1365-2982.2009.01262.x

Polus, M., Montrieux, C., Giet, D., Louis, E., Belaiche, J., & Coche, E. (2009). Le depistage generalise du cancer colorectal: une absolue necessite et une realite imminente en Communaute francaise. Revue Médicale de Liège, 64 (2), 96-102.

Reenaers, C., Louis, E., & Belaiche, J. (2009). Thérapies biologiques et maladies inflammatoires chroniques intestinales. Revue Médicale de Liège, 64 (5-6), 301-304.

Villani, A.-C., Lemire, M., Fortin, G., Louis, E., Silverberg, M. S., Collette, C., Baba, N., Libioulle, C., Belaiche, J., Bitton, A., Gaudet, D., Cohen, A., Langelier, D., Fortin, P. R., Wither, J. E., Sarfati, M., Rutgeerts, P., Rioux, J. D., Vermeire, S., ... Franchimont, D. (2009). Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. Nature Genetics, 41 (1), 71-6. doi:10.1038/ng.285

Villani, A.-C., Lemire, M., Louis, E., Silverberg, M. S., Collette, C., Fortin, G., Nimmo, E. R., Renaud, Y., Brunet, S., Libioulle, C., Belaiche, J., Bitton, A., Gaudet, D., Cohen, A., Langelier, D., Rioux, J. D., Arnott, I. D. R., Wild, G. E., Rutgeerts, P., ... Franchimont, D. (2009). Genetic variation in the familial Mediterranean fever gene (MEFV) and risk for Crohn's disease and ulcerative colitis. PLoS ONE, 4 (9), 7154. doi:10.1371/journal.pone.0007154

Louis, E., Reenaers, C., & Belaiche, J. (2008). Does the phenotype at diagnosis (e.g., fibrostenosing, inflammatory, perforating) predict the course of Crohn's disease? Inflammatory Bowel Diseases, 14, 59-60. doi:10.1002/ibd.20559

Louis, E., Reenaers, C., & Belaiche, J. (2008). Does the behavior of Crohn's disease change over time? Inflammatory Bowel Diseases, 14, 54-55. doi:10.1002/ibd.20561

Louis, E., Reenaers, C., & Belaiche, J. (2008). Are we giving biologics too much time? When should we stop treatment? World Journal of Gastroenterology, 14, 5528-5531. doi:10.3748/wjg.14.5528

Meuwis, M.-A.* , Fillet, M.* , Lutteri, L., Marée, R., Geurts, P., De Seny, D., Malaise, M., Chapelle, J.-P., Wehenkel, L., Belaiche, J., Merville, M.-P.* , & Louis, E.*. (2008). Proteomics for prediction and characterization of response to infliximab in Crohn's disease: a pilot study. Clinical Biochemistry, 41 (12), 960-7. doi:10.1016/j.clinbiochem.2008.04.021

Peeters, H., Cruyssen, B. V., Mielants, H., de Vlam, K., Vermeire, S., Louis, E., Rutgeerts, P., Belaiche, J., & De Vos, M. (January 2008). Gastroenterology - Clinical and genetic factors associated with sacroiliitis in Crohn's disease. Journal of Gastroenterology and Hepatology, 23 (1), 132-137. doi:10.1111/j.1440-1746.2007.05108.x

Reenaers, C., Franchimont, N., Oury, C., Belaiche, J., Malaise, M., Bours, V., Theatre, E., Delvenne, P., & Louis, E. (2008). Sensitivity of intestinal fibroblasts to TNF-related apoptosis-inducing ligand-mediated apoptosis in Crohn's disease. Scandinavian Journal of Gastroenterology, 43, 1334-1345. doi:10.1080/00365520802200010

Dideberg, V., Kristjansdottir, G., Milani, L., Libioulle, C., Sigurdsson, S., Louis, E., Wiman, A. C., Vermeire, S., Rutgeerts, P., Belaiche, J., Franchimont, D., Van Gossum, A., Bours, V., & Syvanen, A. C. (15 December 2007). An insertion-deletion polymorphism in the Interferon Regulatory Factor 5 (IRF5) gene confers risk of inflammatory bowel diseases. Human Molecular Genetics, 16 (24), 3008-3016. doi:10.1093/hmg/ddm259

Belaiche, J., Chapelier, N., Wertz, S., & Louis, E. (2007). Les thérapies innovantes au CHU dans les maladies inflammatoires chroniques de l'intestin (MICI). Revue Médicale de Liège, 62 Spec No, 63-7.

Belaiche, J., Delwaide, J., Polus, M., & Louis, E. (2007). Actualites therapeutiques en hepato-gastroenterologie. Revue Médicale de Liège, 62 (5-6, May-Jun), 303-9.

Daniel, F., Loriot, M. A., Seksik, P., Cosnes, J., Gornet, J. M., Lemann, M., Fein, F., Vernier-Massouille, G., De Vos, M., Boureille, A., Treton, X., Flourie, B., Roblin, X., Louis, E., Zerbib, F., Beaune, P., & Marteau, P. (January 2007). Multidrug resistance gene-1 polymorphisms and resistance to cyclosporine a in patients with steroid resistant ulcerative colitis. Inflammatory Bowel Diseases, 13 (1), 19-23. doi:10.1002/ibd.20046

Libioulle, C., Louis, E., Hansoul, S., Sandor, C., Farnir, F., Franchimont, D., Vermeire, S., Dewit, O., de Vos, M., Dixon, A., Demarche, B., Gut, I., Heath, S., Foglio, M., Liang, L., Laukens, D., Mni, M., Zelenika, D., Van Gossum, A., ... Georges, M. (2007). Novel Crohn disease locus identified by genome-wide association maps to a gene desert on 5p13.1 and modulates expression of PTGER4. PLoS Genetics, 3 (4), 538-543. doi:10.1371/journal.pgen.0030058

Louis, E., Bours, V., Dideberg, V., & Belaiche, J. (2007). Les maladies inflammatoires chroniques intestinales : de la génétique au traitement. Revue Médicale de Liège, 62, 47-51.

Meuwis, M.-A., Louis, E., & Merville, M.-P. (2007). Contribution of proteomics to colorectal cancer diagnosis. Acta Endoscopica, 295-303. doi:10.1007/BF02961919

Piront, P., Louis, E., Belaiche, J., & Polus, M. (2007). Screening for colorectal cancer in 2006. Acta Endoscopica, 37 (3), 305-313. doi:10.1007/BF02961920

Piront, P., Louis, E., Belaiche, J., & Polus, M. (January 2007). Le depistage du cancer colorectal. Revue Médicale de Liège, 62 (1), 15-20.

Urbain, D., De Looze, D., Demedts, I., Louis, E., Dewit, O., Macken, E., & Van Gossum, A. (April 2006). Video capsule endoscopy in small-bowel malignancy: A multicenter Belgian study. Endoscopy, 38 (4), 408-411. doi:10.1055/s-2005-921203

Vanmeerbeek, M., & Louis, E. (2006). Les IPP au très long cours: le problème est-il uniquement économique? Revue Médicale de Liège, 61 (5-6), 483-7.

Vijverman, A., Belaiche, J., & Louis, E. (November 2005). L'anemie chronique dans les maladies inflammatoires de l'intestin: revue de litterature. Revue Médicale de Liège, 60 (11), 888-92.

Ausloos, F., Belaiche, J., & Louis, E. (September 2005). Implication des intolérances et allergies alimentaires dans le syndrome du côlon irritable: quelles sont les evidences? Revue Médicale de Liège, 60 (9), 744-9.

Franchimont, N., Reenaers, C., & Louis, E. (01 April 2005). Infliximab and the bone in Crohn's disease. Alimentary Pharmacology and Therapeutics, 21 (7), 918-919. doi:10.1111/j.1365-2036.2005.02434.x

Gustot, T., Lemmers, A., Louis, E., Nicaise, C., Quertinmont, E., Belaiche, J., Roland, S., Van Gossum, A., Deviere, J., & Franchimont, D. (April 2005). Profile of soluble cytokine receptors in Crohn's disease. Gut, 54 (4), 488-495. doi:10.1136/gut.2004.043554

El Yafi, F., Winkler, R., Delvenne, P., Boussif, N., Belaiche, J., & Louis, E. (March 2005). Altered expression of type I insulin-like growth factor receptor in Crohn's disease. Clinical and Experimental Immunology, 139 (3), 526-533. doi:10.1111/j.1365-2249.2004.02724.x

Laurent, S., Barbeaux, A., Detroz, B., Detry, O., Louis, E., Belaiche, J., & Meurisse, M. (2005). Development of adenocarcinoma in chronic fistula in Crohn's disease. Acta Gastro-Enterologica Belgica, 68 (1, Jan-Mar), 98-100.

Franchimont, N., Reenaers, C., Lambert, C., Belaiche, J., Bours, V., Malaise, M., Delvenne, P., & Louis, E. (December 2004). Increased expression of receptor activator of NF-kappa B ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients. Clinical and Experimental Immunology, 138 (3), 491-498. doi:10.1111/j.1365-2249.2004.02643.x

Franchimont, N., Putzeys, V., Collette, J., Vermeire, S., Rutgeerts, P., De Vos, M., Van Gossum, A., Franchimont, D., Fiasse, R., Pelckmans, P., Malaise, M., Belaiche, J., & Louis, E. (15 September 2004). Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease. Alimentary Pharmacology and Therapeutics, 20 (6), 607-614. doi:10.1111/j.1365-2036.2004.02152.x

Louis, E., El Ghoul, Z., Vermeire, S., Dall'Ozzo, S., Rutgeerts, P., Paintaud, G., Belaiche, J., De Vos, M., Van Gossum, A., Colombel, J. F., & Watier, H. (01 March 2004). Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Alimentary Pharmacology and Therapeutics, 19 (5), 511-519. doi:10.1111/j.1365-2036.2004.01871.x

Dupont, P., Louis, E., & Belaiche, J. (2004). La video-capsule endoscopique: une nouvelle methode d'exploration du grele. Revue Médicale de Liège, 59 (7-8, Jul-Aug), 445-50.

Louis, E., & Belaiche, J. (2004). Natural history and risk factors for colorectal cancer in inflammatory bowel disease. Acta Endoscopica, 34, 231-236. doi:10.1007/bf03009009

Louis, E., Michel, V., Hugot, J. P., Reenaers, C., Fontaine, F., Delforge, M., El Yafi, F., Colombel, J. F., & Belaiche, J. (April 2003). Early development of stricturing or penetrating pattern in Crohn's disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype. Gut, 52 (4), 552-557. doi:10.1136/gut.52.4.552

Polus, M., Piront, P., Jerusalem, G., Sautois, B., Louis, E., Detroz, B., Laurent, S., Belaiche, J., & Fillet, G. (April 2003). Prevention primaire et secondaire du cancer colorectal. Revue Médicale de Liège, 58 (4), 247-53.

Kaskas, B. A., Louis, E., Hindorf, U., Schaeffeler, E., Deflandre, J.-L., Graepler, F., Schmiegelow, K., Gregor, M., Zanger, U. M., Eichelbaum, M., & Schwab, M. (January 2003). Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine. Gut, 52 (1), 140-142. doi:10.1136/gut.52.1.140

Louis, E. (2003). Epidemiology, clinical presentation and diagnostic strategy of gastro-esophageal reflux. Acta Endoscopica, 33, 679-684. doi:10.1007/BF03002605

Louis, E., & Belaiche, J. (2003). Optimizing treatment with thioguanine derivatives in inflammatory bowel disease. Best Practice and Research. Clinical Gastroenterology, 17 (1), 37-46. doi:10.1053/bega.2002.0346

Piront, P., Belaiche, J., & Louis, E. (2003). Revue de l'épidémiologie de la maladie de Crohn en Europe. Acta Endoscopica, 33, 199-205. doi:10.1007/bf03028412

Berlaiche, J., & Louis, E. (December 2002). Severe lower gastrointestinal bleeding in Crohn's disease: Successful control with infliximab. American Journal of Gastroenterology, 97 (12), 3210-3211.

Louis, E., & Belaiche, J. (October 2002). Behaviour of Crohn's disease according to the Vienna classification - Reply. Gut, 51 (4), 614-615.

Louis, E. (September 2002). Pharma clinics le medicament du mois. L'esomeprazole. Revue Médicale de Liège, 57 (9), 610-2.

Vermeire, S., Louis, E., Carbonez, A., Van Assche, G., Noman, M., Belaiche, J., De Vos, M., Van Gossum, A., Pescatore, P., Fiasse, R., Pelckmans, P., Reynaert, H., D'Haens, G., & Rutgeerts, P. (September 2002). Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. American Journal of Gastroenterology, 97 (9), 2357-2363. doi:10.1111/j.1572-0241.2002.05991.x

Delforge, M., Plomteux, O., Delfosse, V., Fontaine, F., & Louis, E. (August 2002). Oesophage de Barrett: mise au point. Revue Médicale de Liège, 57 (8), 535-45.

Laurent, S., Detry, O., Detroz, B., De Roover, A., Joris, J., Honore, P., Louis, E., Belaiche, J., & Jacquet, N. (August 2002). Strictureplasty in Crohn's disease : Short- and long-term follow-up. Acta Chirurgica Belgica, 102 (4, JUL-AUG), 253-255. doi:10.1080/00015458.2002.11679307

Piette, C., Polus, M., & Louis, E. (August 2002). Implications pathologiques du systeme neuroendocrinien digestif. Revue Médicale de Liège, 57 (8), 509-18.

Louis, E., Vermeire, S., Rutgeerts, P., De Vos, M., Van Gossum, A., Pescatore, P., Fiasse, R., Pelckmans, P., Reynaert, H., D'Haens, G., Malaise, M., & Belaiche, J. (July 2002). A positive response to infliximab in Crohn disease: Association with a higher systemic inflammation before treatment but not with-308 TNF gene polymorphism. Scandinavian Journal of Gastroenterology, 37 (7), 818-824. doi:10.1080/713786515

Vermeire, S., Louis, E., Rutgeerts, P., De Vos, M., Van Gossum, A., Belaiche, J., Pescatore, P., Fiasse, R., Pelckmans, P., Vlietinck, R., Merlin, F., Zouali, H., Thomas, G., Colombel, J. F., & Hugot, J. P. (July 2002). NOD2/CARD15 does not influence response to infliximab in Crohn's disease. Gastroenterology, 123 (1), 106-111. doi:10.1053/gast.2002.34172

Esters, N., Vermeire, S., Joossens, S., Noman, M., Louis, E., Belaiche, J., De Vos, M., Van Gossum, A., Pescatore, P., Fiasse, R., Pelckmans, P., Reynaert, H., Poulain, D., Bossuyt, X., & Rutgeerts, P. (June 2002). Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease. American Journal of Gastroenterology, 97 (6), 1458-1462. doi:10.1111/j.1572-0241.2002.05689.x

Louis, E., DeLooze, D., Deprez, P., Hiele, M., Urbain, D., Pelckmans, P., Deviere, J., & Deltenre, M. (March 2002). Heartburn in Belgium: prevalence, impact on daily life, and utilization of medical resources. European Journal of Gastroenterology and Hepatology, 14 (3), 279-284. doi:10.1097/00042737-200203000-00012

Piront, P., Louis, E., Latour, P., Plomteux, O., & Belaiche, J. (February 2002). Epidemiology of inflammatory bowel diseases in the elderly in the province of Liege - A three-year prospective study. Gastroentérologie Clinique et Biologique, 26 (2), 157-161.

Louis, E. (January 2002). Pharma-clinics le medicament du mois. Le rabeprazole (Pariet). Revue Médicale de Liège, 57 (1), 53-6.

Louis, E., Mathieu, A., Oger, A. F., Degroote, E., Aboul Nasr El Yafi, F. A., & Belaiche, J. (December 2001). Behaviour of Crohn's Disease According to the Vienna Classification: Changing Pattern over the Course of the Disease. Gut, 49 (6), 777-82. doi:10.1136/gut.49.6.777

Denis, M. A., Louis, R., Malaise, M., Belaiche, J., & Louis, E. (February 2001). Increased Response of Blood Eosinophils to Various Chemotactic Agents in Quiescent Crohn Disease. Scandinavian Journal of Gastroenterology, 36 (2), 190-5. doi:10.1080/003655201750065951

Belaiche, J., Desager, J. P., Horsmans, Y., & Louis, E. (January 2001). Therapeutic Drug Monitoring of Azathioprine and 6-Mercaptopurine Metabolites in Crohn Disease. Scandinavian Journal of Gastroenterology, 36 (1), 71-6. doi:10.1080/00365520150218084

Postal, A., Detry, O., Louis, E., Hardy, N., Belaiche, J., & Jacquet, N. (2001). Ileo-caecal actinomycosis: Report of a case simulating complicated inflammatory bowel disease. Acta Gastro-Enterologica Belgica, 64 (4, Oct-Dec), 318-320.

Bettiol, J., Bartsch, P., Louis, R., De Groote, D., Gevaerts, Y., Louis, E., & Malaise, M. (December 2000). Cytokine Production from Peripheral Whole Blood in Atopic and Nonatopic Asthmatics: Relationship with Blood and Sputum Eosinophilia and Serum Ige Levels. Allergy, 55 (12), 1134-41. doi:10.1034/j.1398-9995.2000.00711.x

Belaiche, J., & Louis, E. (September 2000). Traitement de la maladie de Crohn de l'adulte par anticorps anti-tumor necrosis factor-alpha (TNF alpha). Revue Médicale de Liège, 55 (9), 827-32.

Van Kemseke, C., Belaiche, J., & Louis, E. (August 2000). Frequently Relapsing Crohn's Disease Is Characterized by Persistent Elevation in Interleukin-6 and Soluble Interleukin-2 Receptor Serum Levels During Remission. International Journal of Colorectal Disease, 15 (4), 206-10. doi:10.1007/s003840000226

Louis, E., & Belaiche, J. (May 2000). Reflux gastro-oesophagien de l'adulte: diagnostic et traitement. Revue Médicale de Liège, 55 (5), 341-4.

Franchimont, D., Martens, H., Hagelstein, M.-T., Louis, E., Dewé, W., Chrousos, G. P., Belaiche, J., & Geenen, V. (August 1999). Tumor Necrosis Factor Alpha Decreases, and Interleukin-10 Increases, the Sensitivity of Human Monocytes to Dexamethasone: Potential Regulation of the Glucocorticoid Receptor. Journal of Clinical Endocrinology and Metabolism, 84 (8), 2834-9. doi:10.1210/jcem.84.8.5931

Belaiche, J., Van Kemseke, C., & Louis, E. (May 1999). Use of the Enteroscope for Colo-Ileoscopy: Low Yield in Unexplained Lower Gastrointestinal Bleeding. Endoscopy, 31 (4), 298-301. doi:10.1055/s-1999-17

Baert, F., Wouters, K., D'Haens, G., Hoang, P., Naegels, S., D'Heygere, F., Holvoet, J., Louis, E., Devos, M., & Geboes, K. (1999). Lymphocytic colitis: a distinct clinical entity? A clinicopathological confrontation of lymphocytic and collagenous colitis. Gut, 45 (3), 375-81. doi:10.1136/gut.45.3.375

Franchimont, D., Louis, E., Dupont, P., Vrindts-Gevaert, Y., Dewé, W., Chrousos, G., Geenen, V., & Belaiche, J. (1999). Decreased Corticosensitivity in Quiescent Crohn's Disease: An Ex Vivo Study Using Whole Blood Cell Cultures. Digestive Diseases and Sciences, 44 (6), 1208-15. doi:10.1023/A:1026644711530

Franchimont, D., Louis, E., Dewé, W., Martens, H., Vrindts-Gevaert, Y., De Groote, D., Belaiche, J., & Geenen, V. (02 January 1998). Effects of Dexamethasone on the Profile of Cytokine Secretion in Human Whole Blood Cell Cultures. Regulatory Peptides, 73 (1), 59-65. doi:10.1016/S0167-0115(97)01063-X

Louis, E., Belaiche, J., Van Kemseke, C., Franchimont, D., de Groote, D., Geenen, V., & Mary, J. Y. (October 1997). A High Serum Concentration of Interleukin-6 Is Predictive of Relapse in Quiescent Crohn's Disease. European Journal of Gastroenterology and Hepatology, 9 (10), 939-44. doi:10.1097/00042737-199710000-00004

Louis, E., Moutschen, M., de Marneffe, P., Malherbe, R., Closon, T., T'Jean, M., Demonty, J., & Belaiche, J. (1997). Extensive Ulcerative Colitis and Extraintestinal Manifestations in a Patient with Hiv Infection and Significant Cd4 T-Cell Lymphopenia. Gastroentérologie Clinique et Biologique, 21 (11), 884-7.

Louis, E., Franchimont, D., Deprez, M., Lamproye, A., Schaaf-Lafontaine, N., Mahieu, P., & Belaiche, J. (1996). Decrease in systemic tolerance to fed ovalbumin in indomethacin-treated mice. International Archives of Allergy and Immunology, 109 (1), 21-6. doi:10.1159/000237227

Louis, E., Satsangi, J., Roussomoustakaki, M., Parkes, M., Fanning, G., Welsh, K., & Jewell, D. (1996). Cytokine gene polymorphisms in inflammatory bowel disease. Gut, 39 (5), 705-10. doi:10.1136/gut.39.5.705

Louis, E., Franchimont, D., Lamproye, A., Van Kemseke, C., Schaaf-Lafontaine, N., Mahieu, P., & Belaiche, J. (September 1995). Systemic Immune Response after Rectocolonic Administration of Ovalbumin in Mice. International Archives of Allergy and Immunology, 108 (1), 19-23. doi:10.1159/000237112

Louis, E., Belaiche, J., Van Kemseke, C., Schaaf-Lafontaine, N., Mahieu, P., & Mary, J. Y. (August 1995). Soluble Interleukin-2 Receptor in Crohn's Disease. Assessment of Disease Activity and Prediction of Relapse. Digestive Diseases and Sciences, 40 (8), 1750-6. doi:10.1007/BF02212697

Louis, E., & Belaiche, J. (1995). Hydroxychloroquine (Plaquenil) for recurrence prevention of Crohn's disease after curative surgery. Gastroentérologie Clinique et Biologique, 19 (2), 233-4.

Louis, E., Louis, R., Drion, V., Bonnet, V., Lamproye, A., Radermecker, M., & Belaiche, J. (1995). Increased frequency of bronchial hyperresponsiveness in patients with inflammatory bowel disease. Allergy, 50 (9), 729-33. doi:10.1111/j.1398-9995.1995.tb01214.x

Delwaide, J., Vivario, M., Belaiche, J., Louis, E., Courtoy, R., Gast, P., & Boniver, J. (1991). Ultrastructural demonstration of histamine in human enterochromaffin like cell granules. Gut, 32 (7), 834. doi:10.1136/gut.32.7.834

Louis, E., Servais, B., & Belaiche, J. (June 1990). L'état inflammatoire physiologique de la muqueuse digestive. Revue Médicale de Liège, 45 (6), 303-10.

Louis, E. (1989). Les intégrines leucocytaires : de la biologie moléculaire à l'immunopathologie et l'immunorégulation. Revue Médicale de Liège, XLIV 20, 615-625.